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By Poonam Dattani 
 




Nanocarriers have been established as delivery vehicles to target cancer tumors.  
However, premature drug leakage is one of the major reasons for inefficient drug delivery of 
nanocarriers to the tumor. Drug diffusion out of the nanocarriers or destabilization of drug 
loaded nanocarriers by physiological interactions with blood cells, serum proteins, and cell 
membranes upon systemic administration contribute to premature drug release.  In this study, 
targeted micelles, liposomes and solid lipid nanoparticles (SLNs) of similar composition 
were prepared and characterized to compare physicochemical characteristics, in vitro 
stability, in vitro release rates in release media and in vivo performance.  Peptide 
Amphiphiles (PAs) formed micelles with critical micelle concentration (CMC) values 
ranging between 23.68 ± 0.72 µM to 38.76 ± 2.27 µM.  Transmission Electron Microscopy 
(TEM) images confirmed the self-assembly of PAs into spherical structures where the largest 
sizes were seen for C16-(PEG2)6-LDV micelles. Dynamic Light Scattering (DLS) results 
confirmed the presence of targeted liposomes and SLNs with sizes smaller than 100 nm.  
Forster Resonance Energy Transfer (FRET) studies revealed that targeted micelles, liposomes 
and SLNs were all stable upon dilution in aqueous medium, however the stability was 
significantly reduced in human serum, with micelles being the least stable and SLNs being 
the most stable.  The same trend was observed for the in vitro release profiles, where targeted 
paclitaxel-loaded micelles (PTX-micelles) had the fastest release rate and paclitaxel-loaded 
SLNs (PTX-SLN) exhibited the slowest release rate. DLS results showed that sizes of PTX-
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SLNs were smaller than PTX-liposomes (80.53 ± 5.37 nm vs 123.31 ± 5.87 nm). Cryogenic 
TEM observation showed increasing size in the order of PTX-micelles (6 to 12 nm) < PTX-
SLNs (10-120 nm) < PTX-liposomes (48-145 nm). Drug Loading Content (DLC) of PTX-
SLNs was greater than PTX-micelles and PTX-liposomes (7.45 ± 0.41 % vs 1.70 ± 0.42 % 
and 0.92 ± 0.09 %).  Compared to initial aqueous dispersions, reconstituted spray dried 
formulations maintained their nanosize and paclitaxel content over 7 days at 4⁰C. In A375 
melanoma xenograft mouse model, the tumor volumes were significantly smaller for mice 
treated with PTX-SLNs compared to the control group. Furthermore, tumor volumes were 
significantly smaller for mice treated with PTX-SLNs compared to those treated with PTX-
micelles and PTX-liposomes.   These studies demonstrate the potential of stable PTX-SLNs 
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Chapter 1: Introduction 
 
1.1 Cancer: Chemotherapy and Limitations 
Cancer is a disease characterized by the uncontrolled growth and spread of abnormal 
cells and it is the leading cause of death worldwide, accounting for an estimated 9.6 million 
deaths in 2018 [1].  The American Cancer Society (ACS) reported that in 2019, there will be 
an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the United 
States [2].  It is also estimated that by 2030, 23.6 million new cases of cancer per year will 
occur, compared to 17 million cases that occurred in 2016 [3].  Treatment modalities of 
localized and metastasized cancer include immunological, photothermal, photodynamic, gene 
and hormone therapy.  Surgery, radiation and chemotherapy are the first line treatment 
options for most types of cancer.  Chemotherapeutic drugs have several limitations, for 
example they lack specificity towards cancer cells which results in toxic effects to healthy 
tissue, including bone marrow suppression, infertility and mucositis.  Furthermore, the high 
distribution volume results in high concentrations of these drugs in healthy tissue.  The 
development of anti-cancer drug formulations is challenging due to their poor aqueous 
solubility.  For example, paclitaxel is hydrophobic and has a very low water solubility (<0.3 
mg/mL), which can result in aggregation upon intravenous administration causing 
embolization of blood vessels.  To overcome this issue, paclitaxel is currently formulated 
with Cremophor EL and dehydrated ethanol which is diluted with saline prior to intravenous 
administration.  However, Cremophor EL is a toxic excipient and has been known to cause 
severe side effects such as hypersensitivity reactions, nephrotoxicity, cardiotoxicity and 
cardiotoxicity [4].  The efficacy of chemotherapeutic agents is also limited due to resistance 
mechanisms.  For example, increased hydrostatic pressure of the tumor interstitium of tumor 
tissue can result in the outward convective interstitial flow resulting in drug transport away 
from the tumor.  Furthermore, cancer cells can acquire resistance to a wide variety of drugs 
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through activation of anti-apoptotic pathways and over-expression of efflux pumps and this is 
known as multidrug resistance (MDR). The main protein involved in MDR is P-glycoprotein 
(P-gp), which is an ATP-dependent transporter located on the cell and nuclear membrane that 
non-selectively binds to neutral or positively charged molecules, of which many 
antineoplastic drugs fall under this category.  The normal physiological role of P-gp is to 
protect the cellular entry of undesirable molecules through efflux mechanisms and to 
transport substances across the cells including drugs, steroids, polypeptides and bile acids.  
However, P-gp is over-expressed in intestinal, liver, pancreas, kidney, ovary and testicular 
cancers, which results in the pumping out of drug molecules from cells, resulting in sub-
optimal therapeutic drug concentrations at the tumor site [5-9]. Overall, these factors 
highlight the necessity for new and more efficacious treatments for cancer. 
1.2 Targeted Drug Delivery of Nanocarriers  
Nanotechnology is an emerging therapeutic platform that is being used for the 
treatment of cancer and has shown great promise in the past few decades.  Nanocarriers have 
gained increased interest over the years due to their ability to overcome obstacles faced with 
conventional chemotherapy, such as non-specificity and severe side effects.  Specifically, 
nanocarriers are colloidal drug carrier systems less than 500 nm in size and can be used for 
encapsulation and delivery of hydrophobic and hydrophilic anti-cancer agents to improve 
bioavailability and therapeutic efficacy [10].  Several advantages of nanocarriers include, 
improved pharmacokinetics, pharmacodynamics and bioavailability, improved solubility and 
stability, ability to protect payload from degradation, facilitation of cellular uptake and 
cellular internalization, decreased non-specific toxicity, controlled release and site-specific 
delivery through active and passive targeting mechanisms.  Furthermore, nanocarriers can 
help to overcome MDR through bypassing of P-gp efflux pumps on the cellular membrane 
[11].   
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1.2.1 Passive targeting.  Targeting of nanocarriers to the tumor tissue is highly 
dependent on the structural differences of normal healthy tissue compared to tumor tissue. 
The pathophysiological abnormalities in the tumor microenvironment allow for the selective 
accumulation of nanocarriers into the tumor tissue.  In healthy tissues, a counterbalance is 
attained between proangiogenic molecules (VEGF) and antiangiogenic molecules 
(VEGFR1).  However, in tumor tissue, new vessels are formed and pro-angiogenic signaling 
is abnormally upregulated to ensure that growing tumor cells receive an adequate supply of 
oxygen and nutrients.  This results in the formation of an abnormal vasculature network, 
characterized by irregular, chaotic, tortuous and leaky blood vessels.  The endothelial surface 
is fenestrated with gaps (10 to 1000 nm) between the endothelial cells, enabling the 
extravasation and selective accumulation of nanocarriers into the interstitial space.  However, 
tight junctions between normal endothelial cells do not allow nanocarriers to extravasate and 
this difference can be exploited to achieve tumor targeted drug delivery.  Furthermore, the 
leaky tumor vasculature enables the extravasation of excess fluid into the tumor interstitium 
and the inability of non-functional lymphatic vessels to drain the excess fluid leads to an 
imbalance in the interstitial fluid pressure (IFP) [12, 13].  The increased vascular 
permeability and poor lymphatic drainage results in the selective accumulation and retention 
of nanocarriers in the tumor tissue and this is known as the Enhanced Permeability and 
Retention (EPR) effect.  Despite these advantages, nanocarrier accumulation and retention 
may vary and have unpredictable outcomes due to the heterogeneity of tumor environment 
and variation in the degree of tumor vascularization and angiogenesis. Additionally, the 
elevated IFP of solid tumors may prevent the uptake and homogenous distribution of drugs in 
the tumor.  Furthermore, nanocarriers can be recognized as foreign and undergo opsonization 
by the cells of the reticuloendothelial system (Mononuclear Phagocyte System, MPS).  These 
factors combined may potentially reduce the bioavailability of drug at the tumor site and 
 23 
reduce the efficacy of these drug delivery systems.  Despite these limitations, there are 
several passive targeted nanocarriers commercially available, which demonstrate the 
potential of nanocarrier drug delivery systems in tumor therapy.  Doxil and Myocet were the 
first liposome products to be approved by the FDA for the treatment of cancer, and were 
designed to improve the PK, PD and bioavailability of doxorubicin, which has a very short 
elimination half-life of 0.2 hours [14].  Myocet is an un-PEGylated liposome product, which 
demonstrated an improved elimination half-life of 2.5 hours. To further prolong the blood 
circulation time PEGylated liposomes were formulated (Doxil) which significantly increased 
the elimination half-life to 55 hours.  Furthermore, Doxil has been shown to reduce 
cardiotoxic effects significantly compared to free doxorubicin [14].    
1.2.2 Active targeting.  Passive targeting strategies have several limitations as  
described above, therefore the development of nanocarriers with improved targeting abilities 
is of interest.  Active targeting strategies are employed by grafting or incorporating ligands 
onto nanocarriers that specifically recognize and bind to receptors over-expressed in tumor 
cells.  This results in enhanced cellular internalization rather than increased tumor 
accumulation.  The most commonly studied targets and their ligands are listed in table 1.3 
[15].  Integrins are transmembrane heterodimeric glycoprotein receptors comprising of 18 a 
and 8 b polypeptide subunits which non-covalently assemble into 24 different combinations 
[16]. Specifically, integrins mediate cell adhesion by interacting and binding to extracellular 
matrix glycoproteins or connective tissue such as fibronectin.  Integrin mediated adhesion 
influences signaling cascades which in turn modulates standard cellular functions such as cell 
growth, motility, differentiation and proliferation.  Collectively, these functions are 
fundamental to tissue integrity and the maintenance of normal cellular functions [17].  Many 
integrin receptors are over-expressed in cancer cells, which has been shown to correlate with 
tumor progression and growth [18].  For examples integrin a4b1 is over-expressed in 
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melanoma cells making it an ideal target for selective delivery of chemotherapeutic agents to 
cancer cells.  This integrin recognizes a short peptide motif Leucine-Aspartic acid-Valine 
(LDV) within ligands fibronectin and VCAM1, which is key for regulating biological activity 
[19-22].  Therefore, employing synthetic peptides such as LDV could potentially be a useful 
strategy to target anti-cancer agents to cancer cells [23].  Peptides provide various advantages 
including therapeutic effects, small size to enhance delivery to the tumor, low risk of immune 
reactivity, ease of synthesis and low cost.  Furthermore, nanocarriers provide a good platform 
for ligand conjugation through grafting or incorporation at controlled densities and 



















1.2.3 Factors influencing drug targeting and delivery of nanocarriers.  The EPR  
effect is influenced by the physicochemical properties of nanocarriers, including size, shape 
and surface charge and this in turn affects cellular uptake, internalization and circulation half-
life.  To increase the efficacy of drug targeting and delivery, the physicochemical properties 
of nanocarriers can be optimized to an ideal range (table 1.4).  
a) Size.  Nanocarriers with sizes above 400 nm will not be able to extravasate into 
 the leaky fenestrations of the endothelial cells due to entrapment in the liver and spleen and 
phagocytosis by macrophages and Kupffer cells of the MPS.  Conversely, nanocarrier sizes 
that are too small (<6 nm) are likely to be excreted by the kidneys.  Larger particles of around 
100 nm may not be able to penetrate deep into the finer vasculature and tissues of the tumor, 
compared to smaller sized nanocarriers of around 20 nm [24]. Cellular uptake is significantly 
influenced by the size of nanocarriers and this was demonstrated by preparing chitosan 
nanoparticles of various sizes and characterizing cellular uptake.  The results showed reduced 
non-phagocytic cellular internalization at sizes above 150 nm and increased phagocytic 
cellular uptake with sizes above 150 nm [25].  Taking these factors into consideration, ideal 
nanocarrier sizes range between 10 nm to 100 nm for optimal drug targeting and delivery. 
b) Surface charge.  The surface charge of nanocarriers also influences phagocytic  
and non-phagocytic cellular uptake, agglomeration, blood circulation time, opsonization and 
renal elimination.  In general, nanocarriers with a zeta potential ≥ + 30 mV or ≤ - 30 mV are 
preferred to maintain good colloidal stability and prevent aggregation in a physiological 
environment.  Positively charged nanocarriers are taken up by cells more effectively 
compared to neutral or negatively charged nanocarriers due to the strong interactions with the 
negatively charged cell membrane.  For example, it was reported that positively charged 
chitosan nanoparticles were more readily internalized in non-phagocytic cells compared to 
negatively charged nanoparticles [25].  However, positively charged nanocarriers are known 
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to have increased blood clearance and cause hemolysis and aggregation of platelets, due to 
opsonization and recognition by the MPS [24].  Also, various positively charged lipids used 
for formulating nanocarriers are cytotoxic through destabilization of the cell membrane, 
therefore careful consideration must be given when selecting materials for formulating 
nanocarriers.  Overall, neutral or negatively charged nanocarriers are preferred due to 
prolonged circulation time, reduced cytotoxicity and evasion of renal elimination.  
c) Shape.  Less extensively studied is the role of nanoparticle geometry on  
drug targeting and delivery.  Most therapeutic carriers under investigation or in clinical 
practice are spherical in shape and this is due to the presumption that size is the principle 
parameter of interest and there is a difficulty in developing methods for non-spherical 
nanoparticles.  The shape of nanoparticles can affect velocity, diffusion and adhesion to 
blood vessel walls.  The targeting ability is also affected due to the available surface area for 
targeting ligands and the degree to which particles fit contours of target cell membranes.  The 
role of geometry on phagocytosis has been studied, where polystyrene nanoparticles of 
various shapes were prepared and tested in alveolar rat macrophages.  Results showed that 
internalization of ellipse-shaped nanoparticles was dependent on the point of attachment, 
where internalization occurred within a few minutes from the pointed end and no 
internalization when in contact with the flat side.  For spherical polystyrene nanoparticles, 
internalization into macrophages occurred at all points of attachment due to symmetry [26].  
These results showed that development of non-spherical nanoparticles may prove to be a 
useful strategy for evading phagocytosis.  The role of geometry on non-phagocytic cellular 
internalization in human cervical carcinoma epithelial HELA cells has also been studied 
through formulation of cubed and cylindrical nanoparticles of various sizes and shapes. 
Results showed that rod-shaped, high aspect ratio (AR=3, d=150 nm, h=450 nm) 
nanoparticles internalized much faster compared to rod-shaped particles with a lower aspect 
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ratio (AR=1, d=200 nm, h=200 nm) [27].  A possible explanation for this is that higher aspect 
ratio particles have larger surface areas for contact with the cell membrane, resulting in faster 
cellular uptake. This is highlighted by another study that reported that antibody coated rod-
shaped nanoparticles compared to spherical were more effective at targeting endothelial cells 
due to the large surface area and thus increased interactions of antibody binding sites to cell 
membrane receptors [28]. 
d) Surface chemistry.  It is well known that less than 10% of nanocarriers  
administered intravenously can reach their target site and this partially due to removal by the 
MPS in the liver and spleen.  Opsonization occurs when antibodies or other substances bind 
to foreign particles, making them more susceptible to phagocytosis and these opsonins 
interact with nanocarriers through electrostatic, ionic, van der waals, hydrophobic and 
hydrophilic forces [29].  In general, nanocarriers that are highly charged and hydrophobic are 
more susceptible to opsonization, and it is therefore essential to modify the surface of 
nanocarriers to help avoid elimination by the immune system and prolong the blood 
circulation time.  One of the most common strategies is to coat the surface of nanocarriers 
with a hydrophilic polymer known as polyethylene glycol (PEG), to produce stealth 
characteristics.  In 1997, Abuchowski reported that PEGylation to bovine liver catalase 
significantly reduced immunogenicity and prolonged blood circulation time and since then 
PEG has been used frequently in nanocarriers such as micelles, liposomes and lipid 
nanoparticles [30].  PEG forms a hydrophilic flexible layer on the surface of nanocarriers 
which prevents adsorption of opsonins by steric hinderance and subsequent disruption of 
nanocarriers.  Depending on the molecular weight, PEG can form mushroom or brush-like 
structures surrounding the nanocarriers.  For example, low PEG (5KDa) densities between 
0.5 to 0.7 mol% form mushroom-like structures to maximize surface coverage.  At higher 
densities, PEG chains extend to avoid overlap with existing PEG chains forming a brush-like 
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model.  There is an optimal range of PEG required to form stable nanocarriers, for example it 
has been reported that thermodynamically stable liposomes are formed when formulated with 
5 to 7 mol% PEG and further increases to above 10 mol% destabilize liposomes due to 
repulsion between PEG chains [31].  The advantageous effects of PEG are clearly 
demonstrated by the two commercially available liposome products Doxil (PEGylated) and 
Myocet (non-PEGylated), where Doxil has a significantly longer blood circulation time 
compared to Myocet [14].  It has also been reported that PEGylated polymeric nanoparticles 
demonstrated higher plasma concentrations and reduced accumulation in the liver compared 
to non-pegylated polymeric nanoparticles.  Furthermore, 10% of nanoparticles were 
remaining 6 hours post injection compared to only 0.4% for non-pegylated NP’s [32].  These 
results clearly demonstrated the importance of modifying the surface of nanocarriers to 

















Nanocarriers are spherical aggregates, ranging between 20 nm to 400 nm in size and 
are commonly used to encapsulate hydrophobic and hydrophilic drugs.  Nanocarriers can be 
classified into two categories: organic and inorganic nanoparticles.  Examples of the latter 
include carbon nanotubes and mesoporous silica nanoparticles, however these are less 
common due to non-biocompatibility and toxicity.  Organic nanocarriers include liposomes, 
micelles, dendrimers, lipid and polymeric nanoparticles and these are generally preferred due 
to low toxicity and biocompatibility of lipid and polymeric materials.  Phospholipids are the 
major component of the biological cell membrane, therefore their biocompatible and 
biodegradable nature makes them key components in drug delivery systems.  The self-
assembly of lipids is dependent on the nature of the hydrophilic and hydrophobic regions and 
the type of nanocarrier formed is largely dependent on the packing constraints of lipids to 
minimize exposure of the hydrophobic regions to the aqueous environment. The geometry of 
a nanocarrier is defined by the packing parameter, where V is the surfactant tail volume, a is 
the effective area per molecule at the interface and l is the surfactant tail length [33].  
Therefore, if these factors are known, the geometry of a nanocarrier can be predicted. 
 
Equation 𝑃 = 𝑉/𝑙 
 
When P=1, a lamellar liquid crystalline structure is formed giving rise to vesicle or liposome 
formation. For example, the biological cell membrane is composed of phospholipids arranged 
in a bilayer or lamellar structure. When P>1, amphiphilic lipids self-assemble to form 
reversed structures such as reversed micelles, reversed hexagonal and reverse cubic 
structures. Packing parameters <1 form normal micelle, hexagonal or cubic phases. 
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1.3.1 Micelles.  Micelles are nanosized (10 nm to 100 nm) colloidal aggregates that  
result from the self-assembly of lipid or polymeric amphiphilic molecules in aqueous 
solution.  At low amphiphilic concentrations, amphiphiles exist as monomers and at higher 
concentrations amphiphiles aggregate to form micelle structures and the concentration at 
which this occurs is known as the Critical Micelle Concentration (CMC).  Micelles are 
dynamic structures that are in continuous equilibrium with monomers, where monomers are 
continually being exchanged between micelles.  During micelle formation, the hydrophobic 
segments of amphiphiles aggregate to form a hydrophobic core that encapsulates and controls 
the release of hydrophobic drugs.  The hydrophilic segment forms a hydrophilic shell, 
ensuring aqueous solubility, stabilization of the micelles and prevention of opsonization and 
uptake by the MPS.  Micelles have several advantages including increased solubility of 
hydrophobic drugs and formulation using a variety of polymeric or lipid amphiphilic 
molecules to fine-tune the CMC and stability of micelles.  Furthermore, the small sizes of 
micelles enable rapid accumulation into the tumor.  Targeting ligands can be grafted onto 
amphiphilic molecules to impart active targeting properties to improve drug targeting and 
delivery to the tumor tissue.  Despite these advantages, micelles have poor drug loading 
efficiency and poor in vivo stability.  For example, surfactant-based micelles exhibit high 
CMC values leading to reduced stability when administered systemically [34].  For this 
reason, various strategies have been employed to improve the stability of micelles including, 
cross-linking and covalent drug entrapment [34, 35].  Compared to surfactant-based micelles, 
polymeric micelles demonstrate significantly lower CMC values and self-assembly occurs at 
concentrations exceeding the CMC.  These systems demonstrate better stability and 
prolonged circulation times in vivo [36, 37].  Some commonly used materials used to form 
micelles include poloxamers, PEG-PLA polymers, PEGylated polyglutamic acid, PEG-PAA 
and lipid-PEG conjugates. 
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1.3.2 Liposomes.  Liposomes are the most widely used nanocarrier systems and  
represent the majority of FDA approved nanomedicine products (table 1.1, table 1.2).  
Liposomes are formed from amphiphilic molecules, composed of a phospholipid bilayer that 
entraps hydrophobic drugs and surrounds a hydrophilic core for entrapping hydrophilic 
drugs.  Liposomes can be formed from natural or synthetic lipids, where multiple bilayers 
result in the formation of large multilamellar vesicles (MLV).  These can be downsized to 
single bilayer liposomes known as small unilamellar vesicles (SUV).  Like micelles, 
liposomes are versatile drug delivery systems as their lipid composition, size, charge and 
surface chemistry can be fine-tuned to achieve optimal drug delivery characteristics.  
Compared to micelles, the size range of liposomes tends to be larger, ranging between 50 nm 
to 500 nm and this range depends on the method of production and the choice of lipids.  The 
surface charge of liposomes depends on the choice of lipids used, for example cationic and 
anionic lipids will produce positively or negatively charged liposomes respectively.  The 
surface chemistry of liposomes can also be modified by coating with PEG polymers to help 
evade the immune system and prolong blood circulation.  Liposomes can also be grafted with 
targeting ligands to impart specific targeting properties.  Despite these advantages, drug 
loading in liposomes remains a challenge, where encapsulation of hydrophilic drugs is low 
and requires active loading techniques to increase the drug loading efficiency.  Furthermore, 
encapsulation of hydrophobic drugs inside the bilayer was shown to destabilize the lipid 
bilayer membrane resulting in aggregation and instability of vesicles [38].  Like micelles, 
liposomes also have the potential to become unstable upon in vivo administration.  For 
example, lipids with low transition temperatures result in a more fluid-like flexible membrane 
structure which increases the permeability and drug leakage from the membrane at 
physiological body temperature. 
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1.3.3 Solid lipid nanoparticles.  SLNs are nanosized colloidal structures with sizes  
ranging from 50 to 1000 nm.  Typically, SLNs are composed of a solid lipid phase stabilized 
by a surfactant.  Examples of lipids used are triglycerides, free fatty acids, fatty acid alcohols, 
waxes and steroids, which are all used for dispersion and entrapment of hydrophobic drugs. 
The lipid molecules are solid at room and body temperatures, which enables them to have 
better stability and prolonged drug retention compared to micelles and liposomes.  SLNs 
have several advantages, that include excellent physically stability, good release profiles, 
high drug loading capacity, biodegradability and non-toxicity of lipid carriers.  However, 
despite these advantages SLNs can become unstable through gelation, lipid particle growth 
and polymorphic transitioning [39]. 
1.4  Significance and Statement of the Problem  
Despite the development of numerous anti-cancer nanocarriers in the pre-clinical 
phase, very few have been successfully developed and approved for clinical use.  This is due 
to the low delivery efficiencies of anti-cancer nanomedicines to the tumor which is 
highlighted by a recent meta-analysis of pre-clinical data suggesting that a median of 0.7% of 
the injected dose of nanocarriers reaches the target tumors [40, 41].  One of the major reasons 
for low delivery to the tumor is the poor stability of anti-cancer drug-loaded nanocarriers. 
Upon systemic administration, drug diffusion out of the nanocarriers or interactions with 
blood cells, cellular membranes, serum proteins and other biomacromolecules can result in 
premature drug release before reaching the target tumor site. Therefore, developing a stable 






1.5  Purpose 
 
The purpose of this dissertation is to develop targeted micelles, liposomes and SLNs 
of similar composition and to evaluate their potential by comparing physicochemical 
characteristics, in vitro stability, in vitro release rates and in vivo efficacy.  These studies will 
provide a more comprehensive evaluation of the stability of different types of nanocarrier 
systems, providing further insights into the selection of suitable nanocarrier systems for 
clinical development.   
1.6  Specific Aims 
 
The specific aims of this dissertation are as follows: 
Aim 1: To design, prepare and characterize LDV-targeted micelles, liposomes and solid lipid 
nanoparticles of similar composition. 
Aim 2: To compare the in vitro stability and in vitro drug release of LDV-targeted micelles, 
liposomes and solid lipid nanoparticles.  The stability of micelles, liposomes and solid lipid 
nanoparticles can be assessed in aqueous medium and biological media using Forster 
Resonance Energy Transfer (FRET).  Anti-cancer drug paclitaxel can be loaded into micelles, 
liposomes and solid lipid nanoparticles and in vitro release characteristics can be determined.  
Nanocarriers can also be spray dried to maintain long-term stability. 
Aim 3: To compare the in vivo anti-tumor efficacy of selected LDV-targeted paclitaxel-













Chapter 2: Design and Synthesis of LDV Peptide Amphiphiles  
 
2.1 Introduction  
Amphiphiles are composed of hydrophobic and hydrophilic regions which self-
assemble in aqueous solutions to form a variety of structures including micelles and vesicles. 
Amphiphiles can be characterized by the hydrophilic-lipophilic balance (HLB), which is an 
empirical parameter indicating the degree of hydrophilicity and lipophilicity.  HLB is related 
to the number, weight of hydrophobic and lipophilic groups as well as the structure of the 
amphiphile and there are several methods that can be used to determine this value [42]. 
Typically, for non-ionic surfactants, the HLB scale ranges between 1 and 20.  For ionic 
surfactants, the HLB scale ranges between 0 to 40, where 0 indicates complete 
hydrophobicity and 40 indicates a stronger hydrophilic character of the amphiphile.  The 
HLB of amphiphiles must be optimum to enable formation of micelles and this can be 
achieved by altering the hydrophobic and hydrophilic segments.  Therefore, determination of 
HLB values can be used to predict surfactant properties and those surfactants with HLB 
values within the scale can be used to assess the potential self-assembly into micelles.  In this 
study, novel PAs were designed, where the hydrophobic region is composed of a C16 fatty 
acid chain and the hydrophilic region is comprised of tripeptide LDV targeting region and 
ethylene oxide linker units (Figure 2.1).  PAs were selected for synthesis based on optimum 
HLB values and assessed for their ability to form micelles.   The general process of Solid 
Phase Peptide Synthesis (SPPS) is illustrated in figure 2.2 and involves the building of a 
peptide chain on a solid resin.   The first amino acid already attached to the resin is coupled 
with subsequent amino acids using a series of deprotection and coupling steps.  Specifically, 
this involves the deprotection of temporary protecting groups on the N-terminal of the resin-
attached amino acid and subsequent coupling of the next amino acid.  This process is 
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repeated until the desired peptide sequence is obtained, followed by detachment of the 
peptide from the resin. 
2.2  Materials 
Peptide materials: Fmoc-L-Val-Wang resin, Fmoc-L-Asp-OH, Fmoc-L-leu-OH, 
Fmoc-8-amino-3,6-dioxaoctanoic acid (Fmoc-ADA-OH), 1-[Bis(dimethylamino)methylene]-
1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU), 
Hydroxybenzotriazole (HOBt), (benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate (PyBOP), N,N-Diisopropylethylamine (DIPEA), N,N′-
Diisopropylcarbodiimide (DIC) were purchased from Chem-Impex International, Inc (IL, 
USA). Solvents used were of HPLC grade, dichloromethane (DCM), Dimethylformamide 
(DMF) and acetonitrile were purchased from fisherscientific (PA, USA).  Piperidine, 
trifluoroacetic acid (TFA), Triisopropyl silane (TIS) and stearic acid were obtained from 
Acros organics (NJ, USA) and used as supplied. 
2.3 Method 
2.3.1 Design of PAs and calculation of HLB values.  Three PAs were designed  
with varying lengths of hydrophilic linker units: C16-(PEG2)2-LDV, C16-(PEG2)4-LDV, 
C16-(PEG2)6-LDV (Table 2.1). To predict surfactant properties of PAs, the HLB values for 
each PA was calculated using the Davies method (Table 2.2) [42]. This method was chosen 
since it is useful for calculating HLB values of ionic surfactants.  The carboxylic acid groups 
of PAs are ionized at physiological pH 7.4 and thus the overall net charge of -1 makes the PA 
an anionic structure.  This method takes into account the hydrophilicity and hydrophobicity 
of chemical groups using a parameter group number. Each chemical group is assigned a 
group number, which can be used to calculate the HLB value using equation 2.  For all PAs, 
carboxylic acid groups present in the peptide and oxygen present in the ethylene oxide linker 
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𝑯𝑳𝑩 = 𝟕 ++(𝒉𝒚𝒅𝒓𝒐𝒑𝒉𝒊𝒍𝒊𝒄	𝒈𝒓𝒐𝒖𝒑	𝒏𝒖𝒎𝒃𝒆𝒓𝒔) +	+(𝒉𝒚𝒅𝒓𝒐𝒑𝒉𝒐𝒃𝒊𝒄	𝒈𝒓𝒐𝒖𝒑	𝒏𝒖𝒎𝒃𝒆𝒓𝒔) 
 
2.3.2 Solid Phase Peptide Synthesis of peptide amphiphiles.  PAs were  
synthesized using standard Fmoc-chemistry in a polypropylene vessel on a peptide synthesis 
shaker.  Briefly, wang resin preloaded with valine (Fmoc-L-Val-WR) was soaked in DMF for 
30 minutes to swell the resin.  Next, the protecting group Fmoc was removed from the amino 
group of L-valine by incubating with 20% piperidine in DMF for 30 minutes. The resin was 
then washed with DMF and DCM three times each.  Following deprotection, Fmoc-L-Asp-
OH was coupled to valine at a molar ratio of 3 by treating with DIC and HOBT in DMF for 3 
hours.  The same deprotection-coupling steps were used for the coupling of Fmoc-L-leu-OH. 
Next, two, four or six Fmoc-ADA-OH (PEG2) linker units were coupled to L-leucine by 
treating with HATU, HOBT and DIPEA in DMF for 3 hours.  For conjugation of palmitic 
acid, the Fmoc group was removed from the final PEG2 linker unit using 20% piperidine in 
DMF and the resin was washed using the same procedure as described above. The resin was 
then treated with a mixture of PyBOP and DIPEA in DMF:DCM (50:50) for 3 hours. The 
resin was then washed and the PA was cleaved from the resin by adding a mixture of 
TFA:TIS:H20 (95:2.5:2.5) for 3 hours.  The mixture was removed from the peptide synthesis 
vessel and TFA was evaporated using nitrogen gas until <0.2 ml of solution was remaining. 
Cold isopropyl ether was added to precipitate out the crude PA, which was separated from 
isopropyl ether using centrifugation at 3000 rpm.  Crude PAs were then suspended in DI 
water, lyophilized and subsequently purified by reverse phase High Performance Liquid 
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Chromatography (RP-HPLC) using an Agilent 1200 HPLC system equipped with a diode 
array detector (DAD).  Samples were dissolved in methanol and loaded onto a zorbax agilent 
C-18 column (4.6 x 150mm, 5µm) equilibrated with 90% eluent A (0.1% TFA in water) and 
10% eluent B (0.1% TFA in acetonitrile) for 30 minutes.  PAs were eluted using a linear 
gradient method of 10 to 95% eluent B in 20 minutes at 1.0 mL/min.  The eluate was 
monitored at 280 nm.  The PAs were then re-lyophilized for 48 hours and the lyophilized 
powders were stored at -80°C.  The identity of PAs was confirmed by ESI-MS (Electro Spray 
Ionization Mass Spectrometry). 
2.4 Results and Discussion   
The results show that all PAs have HLB values ranging between 36.55 and 37.45, 
which is within the HLB scale for ionic surfactants (table 2.3).  The results also show that as 
the number of PEG2 units increases, the HLB value increases.  PAs with two, four and six 
PEG2 linkers were chosen for synthesis and characterization as they are within the HLB scale 
and have high HLB values that may improve the aqueous solubility of PAs without PEG2 
linkers.  Mass Spectrometry confirmed the formation of all PAs.  The spectrum displayed the 
protonated molecular ion peak [M+H]+ at m/z 874.57 for C16-(PEG2)2-LDV (Figure 2.3).   
For C16-(PEG2)4-LDV, the major peak is shown at 1186.6 m/z corresponding to the sodiated 
molecule [M+Na]+.  Similarly, the peak at 605 Da is representative of the doubly charged 
sodiated PA [M+2Na]2+ (figure 2.4). The presence of C16-(PEG2)6-LDV was confirmed by 
doubly charged protonated molecular ion peak [M+H]2+ at 728.1 m/z and a doubly charged 
protonated sodiated ion [M+H+Na]+2 at 739 m/z (figure 2.5).  HPLC purity of all PAs were 
>95%.  PAs were further characterized for self-assembly into micelles and incorporation into 





















Figure 2.1: Chemical structure of LDV- peptide amphiphile 
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Hydrophilic groups Lipophilic groups 
Chemical group Group number Chemical group Group Number 
-SO4Na+ 38.7 -CH2 0.475 
-COO-H+ 21.2 -CH3 0.475 
-COO-Na+ 19.1 -CH 0.474 








Figure 2.2: Flow chart for solid phase peptide synthesis steps and LDV peptide 
amphiphile characterization 
STEP 1
Swelling of solid phase resin pre-loaded with 
C terminal amino acid Fmoc-L-Valine
STEP 2
Fmoc deprotection




Coupling of PEG2 linkers
STEP 4
Coupling of palmitic acid
STEP 5




Identification by Mass Spectrometry (MS)
STEP 8
Purification by HPLC
Fmoc-deprotection with 20% piperidine in DMF 
Coupling with DIC/HOBT in DMF 
Fmoc-deprotection with 20% piperisine in DMF 
Coupling with HATU/HOBT/DIPEA in DMF 
Coupling with PyBOP/DIPEA in DMF/DCM   
Cleavage cocktail: TFA:TIS:H20 
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Figure 2.4: ESI-MS spectrum of C16-(PEG2)4-LDV peptide amphiphile 
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Figure 2.5: ESI-MS spectrum of C16-(PEG2)6-LDV peptide amphiphile 
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Chapter 3: Design and Preparation of LDV-targeted Nanocarriers  
 
3.1 Introduction 
A major challenge associated with nanotechnology for cancer therapy is  
the retention of drug inside nanocarriers following intravenous administration, as drug should 
remain inside or complexed to the nanocarrier until it reaches the target cancer cells.  The 
most extensively studied nanocarriers are micelles and liposomes and the stability of these 
systems is a critical factor for effective drug delivery.  Micelles are attractive drug delivery 
vehicles and have several advantages such as small size for exploiting the EPR effect, 
hydrophobic core for loading of poorly soluble anti-cancer agents and hydrophilic shell for 
stability resulting in long circulation kinetics.  The chemical composition and molecular 
weight of the amphiphiles can also be adjusted to achieve effective drug release behavior, 
physical stability and drug loading [43].   However, poor stability is a significant challenge 
that hampers the clinical translation of micelles.  Specifically, micelles are dynamic systems 
and dilution upon intravenous administration can reduce surfactant concentrations below the 
CMC, resulting in premature drug release before reaching the target tumor site.  Micelles are 
also prone to dissociation through interactions with blood components such as albumin and 
apolipoproteins.  Compared to micelles, liposomes have several advantages: they are able to 
encapsulate both hydrophilic and hydrophobic drugs and they are mechanically stronger 
making them less prone to breakage and dissociation upon dilution [44].  However, the use of 
liposomes is also limited by disadvantages such as drug leakage from the bilayer membrane, 
poor physical stability, low encapsulation efficiency, short shelf-life and destabilization 
through interactions with serum proteins.  Compared to liposomes and micelles, SLNs have 
the potential to provide better control over drug release and drug delivery since the lipid 
components are solid at both room and body temperature. This enables improved retention of 
drug molecules inside the nanocarrier, reduced leakage of drug molecules and prolonged 
 50 
release of drug molecules in vivo.  SLNs also have good physical stability and good in vitro 
release characteristics.  However, SLNs also have several disadvantages including 
unpredictable gelation tendency, polymorphic transitioning and low drug loading efficiency 
[45].  Therefore, there is a necessity to develop nanocarriers that are better able to retain the 
drug before reaching the target site, are resistant to disruption from interactions with serum 
proteins and therefore offer better control over drug release and drug delivery.  To develop 
nanocarriers with optimum physicochemical characteristics, the size, charge and morphology 
can be determined to help understand or predict the in vivo behavior of nanocarriers.  For 
determination of size, Transmission Electron Microscopy (TEM) and Dynamic Light 
Scattering (DLS) are commonly used.  DLS measures the hydrodynamic diameter of 
nanocarriers dispersed in aqueous solution and this method is widely preferred due to the 
non-invasive fast measurement times and size determination of nanocarriers in its native 
colloidal state.  This method typically relies on Rayleigh Scattering from the nanoparticles in 
solution that are undergoing Brownian motion [46].  This is the random movement of 
particles in a liquid that occurs as a result of the continuous bombardment from solvent 
molecules of the surrounding medium.  In general, larger particles move more slowly in 
solution compared to smaller particles and the velocity of brownian motion is defined the 
translational diffusion coefficient.  Therefore, the size of the nanocarrier refers to how the 
particle diffuses within the solution and can be calculated from the translation diffusion 
coefficient using the Stokes-Einstein equation [46, 47]: 
 




Where d(H) is the hydrodynamic diameter, D is the translational diffusion coefficient, k is the 
Boltzmann’s constant, T is the absolute temperature and η is the viscosity. Despite frequent 
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use of this method, DLS has several limitations such as poor resolution of particle sizes and 
the inability to determine nanocarrier morphology, porosity and all particle populations 
present in a polydisperse sample.  In contrast, TEM helps to overcome these disadvantages 
by direct observation of samples, which allows for morphology characterization as well as 
size determination.  The morphology of nanocarriers is a characteristic that has been shown 
to dictate the efficacy of targeting and cellular uptake.  It was shown that antibody coated 
rod-shaped nanoparticles compared to spherical were more effective at targeting endothelial 
cells due to the large surface area and thus increased interactions of antibody binding sites to 
cell membrane receptors [28].  For size and morphology characterization, nanocarrier 
samples are adsorbed onto a support film, followed by negative staining to view dehydrated 
structures under an electron beam.  Negative staining can be achieved by applying heavy 
metals salts to the sample, where the hydrated regions in and around the particle become 
occupied.  As the stain is dried, an amorphous electron-dense replica of the particle is 
formed.  Upon imaging, the electron beam primarily interacts with the stain, enhancing the 
contrast of the image, where the image is light in areas occupied by the nanocarrier and dark 
in areas surrounding the nanocarrier.  Despite the usefulness of this method, sample 
preparation is expensive, time consuming and requires drying of nanocarriers.  This can cause 
the sample to shrink, break down or agglomerate, producing a sample image that is no longer 
representative of the native colloidal state [48].  In addition to size and morphology, the 
charge or zeta potential is a fundamental parameter that dictates nanocarrier behavior such as 
aggregation, interaction with cell membranes and other surfaces such as serum proteins [49]. 
The zeta potential is defined as the difference in the electrical potential on the shear surface 
of the nanocarrier and the electrical potential of the solution and is determined by an 
electrophoresis experiment that measures the velocity of the nanocarriers using Laser 
Doppler Velocimetry (LDV).  This is followed by application of the Henry equation to 
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calculate the zeta potential (Equation 3.2), where z is the zeta potential, U is the 
electrophoretic mobility, 𝜀 is the dielectric constant, η is the viscosity and f(ka) is Henry’s 
function [47]. Positively charged or neutral nanocarriers will be preferentially taken up by the 
negatively charged membrane, although cationic lipids and polymers are known to be toxic to 
cells.   
 




PAs were assessed for their ability to self-assemble into micelles.  At low surfactant 
concentrations, surfactant molecules exist as monomers and adsorb at the liquid surface.  As 
the concentration of surfactant increases, the surface tension of the solution decreases and the 
surface becomes saturated with surfactant molecules.  Upon further addition of surfactant, 
surfactant monomers start to self-assemble into micelles and the concentration at which this 
occurs is known as the Critical Micelle Concentration (CMC).  PAs were predicted to have 
amphiphilic properties from calculated HLB values and so it was hypothesized that these PAs 
would self-assemble into micelles, where the fatty acid chains aggregate away from the 
aqueous solution to form a hydrophobic core and the LDV-PEG2 region faces the aqueous 
solution forming a hydrophilic corona (figure 3.1).  The CMC can be determined by 
determining the concentration at which an inflection point occurs when physicochemical 
properties such as surface tension are plotted as a function of concentration.  Light scattering 
methods can also be used, where a sharp increase in turbidity is observed.  A commonly used 
method for CMC determination is known as the fluorescence probe technique.  Here, a 
hydrophobic fluorescent dye known as pyrene, demonstrates sensitivity to the polarity of the 
surrounding medium and consequent changes in spectral properties [50].  Below the CMC, 
pyrene is solubilized in water and above the CMC, when micelles are forming, pyrene 
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partitions into the hydrophobic core.  As a result, the pyrene emission spectrum exhibits 
changes in fluorescent intensity and vibrational structure of emission spectrum.  Specifically, 
there are 5 vibrionic bands.  The intensity of the third (383 nm) vibrionic band is significantly 
enhanced in a hydrophobic environment and the intensity of the first peak is increased in a 
polar environment (figure 3.7).  Therefore, the ratio of the 3rd and 1st peak intensities in the 
emission spectrum provides a measure of the apparent polarity of the environment.  An 
increase in this ratio, indicates a decrease in polar environment of the pyrene.  The CMC can 






Figure 3.1: Schematic representation of the structure and formation of micelles from LDV-




To compare the stability of liposomes with micelles, the lipid compositions must be a  
similar as possible.  Micelles are formed from single chain amphiphiles, due to steric effects 
of the hydrocarbon chain and steric conditions determined by the charged head group.  In 
contrast, double-chained amphiphiles favor the formation of bilayers, due to the steric 
restriction associated with the second hydrocarbon chain [51].  For micelle formation, single 
chain palmitic acid was conjugated with peptide-linker segments to confer amphiphilic 
properties. To form liposomes of similar composition to these micelles, palmitic acid derived 
double-chain amphiphilic phospholipids can be used, ensuring that the fatty acid chain length 
of micelles and liposomes are kept the same. Based on this rationale, a synthetic phospholipid 
named dipalmitoylphosphatidylcholine (DPPC) was selected for liposome formation since it 
is composed of two palmitic acid fatty acid chains attached to a phosphatidylcholine head-
group, enabling the formation of a phospholipid bilayer.  To impart similar head group 
properties, PAs were incorporated into DPPC liposomes.  It was hypothesized that the 
palmitic fatty acid chain of PAs would insert into the DPPC bilayer, facilitating the anchoring 
of the hydrophilic (PEG2)n-LDV head group to the liposome surface (figure 3.2).  The two 
most common methods to produce liposomes are sonication and extrusion, where each 
method produces different mean sizes and size distributions.  Thin lipid films or lipid cakes 
are hydrated in aqueous medium and stacks of crystalline bilayers become fluid and swell.  
The hydrated lipid sheets detach during agitation and self-close to form MLVs, which are 
heterogenous in size and number of lamellae and range between a few hundred nanometers to 
several microns.  MLVs are concentric bilayers separated by narrow aqueous spaces and can 
be downsized to SUVs ranging between 20 nm to 100 nm by energy input in the form of 
sonic energy or mechanical energy.   For sonication, acoustic energy is applied to lipid 
suspensions from a bath or probe tip sonicator.  Smaller sized liposomes can be produced by 
increasing the sonication time and this process is relatively fast.  For application of 
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mechanical energy to produce liposomes, a lipid suspension is passed through a 
polycarbonate membrane with a specific pore size, and this results in vesicle sizes close to 
the diameter of the pore size.  Compared to sonication, this process is slower but produces 


























Figure 3.2: Schematic representation of the structure and formation of liposomes from LDV-




To design SLNs of similar composition to micelles and liposomes, a palmitic acid  
derived solid lipid was used to form the hydrophobic solid core component.   Tripalmitin is a 
triglyceride obtained by acylation of three hydroxy groups of glycerol by palmitic acid 
(C16:0/C16:0/C16:0).  The high melting point of tripalmitin (66⁰C to 68⁰C) means that at 
room temperature and physiological body temperature, tripalmitin is solid, which may 
significantly reduce the mobility of drug molecules within the lipid core, preventing 
premature drug release. To stabilize the solid lipid core and impart targeting properties, PAs 
were incorporated (figure 3.3).  SLNs can be prepared via a variety of methods including 
high pressure homogenization (HPH), solvent emulsification/evaporation, supercritical fluid 
technology, ultrasonication or high-speed homogenization.  Many of these methods after 
often characterized by poorly controlled conditions, which lead to poly-disperse sizes and 
size distributions.  Microfluidic technology has been shown to overcome these disadvantages 
by providing better control of particle sizes and stability of lipid nanoparticles through 
optimization of parameters such as the Flow Rate Ratio (FRR), the total flow rate (TFR), 
choice of solvents, temperature and microfluidic chip design [53-60].  A typical microfluidic 
micro-mixer contains a microfluidic cartridge comprising of moulded channels with 
staggered herringbone structures.  The microfluidic chips are designed to have two inlet 
channels that merge into a microchannel, where one channel is used to pump lipid mixtures 
in ethanol and the second channel is used to pump aqueous solutions.  SLNs are formed when 
these two phases mix through staggered herringbone microchannels, in which chaotic flow 
occurs subjecting the fluid to a repetitive series of a rotational flow profile.  This design 
increases the rate of mixing because the grooves cause the streams of fluid to twist over each 
other, allowing rapid and controlled mixing of both phases.  During mixing, when a specific 






Figure 3.3:  Schematic representation of the structure and formation of solid lipid 
nanoparticles from LDV peptide amphiphiles and tripalmitin lipid in aqueous solution, using 
microfluidic technology.   
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3.2 Materials 
PAs were synthesized as described in section 2. DPPC lipids and liposome extruder 
was purchased from Avanti polar lipids (AL, USA). Tripalmitin and pyrene was purchased 
from Sigma-Aldrich (MO, USA).  Solvents including DCM, methanol, ethanol and 
chloroform were purchased from fisherscientific (Pittsburg, PA). Copper formvar 200 mesh 
grids were purchased from Ted Pella Inc (Redding, CA) 
3.3 Methods 
3.3.1 Liposome preparation.  Liposomes were formed by thin-film hydration. A  
mixture of DPPC and PA were dissolved in chloroform: methanol = 2:1 (v/v) at a molar ratio 
of 1:0.05.   Organic solvents were evaporated to dryness under a stream of nitrogen gas and 
solvent traces were removed by leaving the glass tubes under vacuum overnight.  The dried 
lipid film was then hydrated by the addition of DI water at a temperature between 50⁰C to 
55⁰C, followed by vortexing periodically for 30 minutes to detach any lipid from the glass 
surface. Hydration was carried out in a water bath and the temperature was maintained above 
the main phase transition temperature (Tm) of lipids (41⁰C for DPPC).  This process resulted 
in the formation of MLVs, which were subjected to six freeze-thaw cycles with liquid 
nitrogen and heated DI water.  MLVs were downsized by extruding 21 times through 0.1µm-
pore polycarbonate filters to produce SUVs.  Liposomes were prepared for each PA (C16-
(PEG2)2-LDV, C16-(PEG2)4-LDV, C16-(PEG2)6-LDV) and each liposome composition was 







3.3.2 Solid lipid nanoparticle preparation.  The NanoAsssmblr (Benchtop,  
Precision NanoSystems Inc., Vancouver, Canada) was used to prepare SLNs by microfluidic 
mixing.  Specifically, a microfluidic cartridge comprising of moulded channels with 
staggered herringbone structures was used to formulate SLNs by mixing of the organic 
(tripalmitin in ethanol) and aqueous (PA in water) phases at a molar ratio of 1:0.5.  The 
organic and aqueous phases were pumped into two inlets of the microfluidic chip using 
disposable syringes and mixing was controlled by setting the FRR to 3:1 and the TFR to 15 
mL/min.  At all steps of preparation, the organic and aqueous phases were kept at 75⁰C by 
keeping solutions in the oven and installing a heat block into the NanoAssemblr instrument. 
Next, the mixture was collected from the NanoAssemblr and transferred into a G2 slide-A-
Lyzer dialysis cassette (MWCO 10,000) and dialyzed against DI water to remove traces of 
ethanol. Specifically, the dialysis membrane was hydrated in DI water for 2 minutes prior to 
insertion of SLN sample.  The dialysis cassette was stirred in DI water, which was exchanged 
every hour for 3 hours. Post-dialysis, the sample was removed from the dialysis cassette and 
used for further characterization.  SLNs were prepared for each PA (C16-(PEG2)2-LDV, C16-
(PEG2)4-LDV, C16-(PEG2)6-LDV) and all SLN compositions were prepared in triplicate. 
3.3.3 Characterization of micelles, liposomes and solid lipid nanoparticles. 
a) Determination of the critical micelle concentration (CMC).  The CMC was  
determined using the pyrene fluorescence method.  Stock solutions of PA were prepared in 
methanol at 2 mg/mL and calculated volumes of the stock solutions were added to glass 
scintillation vials.  Next, a stock solution of pyrene in dichloromethane was prepared at 
0.6µM and 50µl of this solution was added to each vial.  The mixture was vortexed to ensure 
a homogenous solution of PAs and pyrene.  Organic solvents were evaporated under a stream 
of nitrogen gas and left under a fume hood overnight to form a thin film of PA and pyrene.  
The dry films were then hydrated with DI water to achieve PA concentrations ranging 
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between 0.01µM to 100µM.  Samples were equilibrated in a water bath at 37⁰C and shaken at 
85 rpm.  Following equilibration, the fluorescence spectra was recorded using a 
spectrofluorometer (Shimadzu Spectrofluorometer RF-5301 PC Shimadzu corporation, 
Pleasanton, USA).  Samples were measured at an excitation wavelength of 337 nm and an 
emission wavelength range of 350 nm and 500 nm. The first (I1) 373 nm and third (I3) 383 
nm vibrionic emission peak fluorescence intensities were recorded and the ratio of the third 
and first vibrionic emission peak fluorescence intensities was plotted against log 
concentration of PAs.   This method was carried out for all three PAs (C16-(PEG2)2-LDV, 
C16-(PEG2)4-LDV, C16-(PEG2)6-LDV) and all experiments were performed in triplicate. 
b) Size, PDI and charge characterization of micelles, liposomes and SLNs.  The  
size, PDI and zeta potential of blank liposomes and blank SLNs were determined using DLS 
on the Zetasizer ZS 90 (Malvern Instruments, Ltd., Malvern, UK). For nanocarrier size and 
PDI, measurements were taken in a disposable microcuvette at 25°C.  For zeta potential, 
samples were diluted in DI water and inserted into a disposable folded capillary zeta cell 
using a syringe.  For each sample, measurements were taken three times using the auto run 
setting. The morphology and size of blank micelles was determined using TEM on a Philips 
CM120 BioTwin.  Micelles were prepared from PAs as described above.  A drop of each 
micelle solution was placed onto a formvar 200-mesh copper grid coated with carbon and left 
to dry in open air.  Next, the sample was stained using a drop of 2% w/v phosphotungstic acid 
(pH 3) to enhance the contrast of the sample and excess solution was removed using filter 
paper.  After air-drying, the copper grid was transferred onto the microscope sample holder 





3.4 Results and Discussion    
The formation of micelles is a thermodynamic process and is driven by the increase in 
entropy when hydrophobic regions of the amphiphile are removed form water and aggregate 
to form a hydrophobic core.  This hydrophobic effect decreases the ordered structure of the 
water molecules that surround the micelle structure, to attain a minimum free energy state.  
Micelles are formed at the CMC, which is characterized by an inflection point when 
physicochemical properties such as surface tension undergo sharp changes at a specific 
surfactant concentration.  Factors that influence micellization include, the structure and 
length of the hydrophobic and hydrophilic regions, electrolyte addition and temperature.  In 
general, an increase in length of the hydrocarbon chain results in an increase in micelle size 
and a decrease in the CMC.  An increase in hydrophilic head group length (ethylene oxide 
chain length) renders micelles more hydrophilic with higher CMC values.  In this study, the 
CMC was determined at 37⁰C in water using the pyrene fluorescence probe method and all 
three PAs formed micelles with a CMC ranging between 23.7µM to 38.8µM (table 3.1 and 
figures 3.4 to 3.6) which are typical values for low molecular weight surfactants. Micelles 
with the largest number of PEG2 linker units (C16-(PEG2)6-LDV) had the largest CMC 
values.  This can be explained by the fact that micelle formation is a result of a balance of 
intermolecular forces, where attractive forces occur through hydrophobic interactions 
between hydrophobic fatty acid chains and repulsive forces arise from steric or electrostatic 
interactions between the polar PEG2-LDV head groups [61, 62].  As the number of PEG2 
units increases, the repulsive interactions are larger compared to the hydrophobic interactions 
and thus larger concentrations of PAs are needed to form micelles [63, 64].  In contrast, 
micelles with lower CMC values (C16-(PEG2)2-LDV, C16-(PEG2)4-LDV) are more resistant 
to dissociation upon dilution.  The size of micelles was not determined by DLS and this is 
likely due to the dynamic nature of micelles and difficulty in determining micelle size in the 
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presence of two populations (micelle aggregates and monomers).  Therefore, direct 
observation of micelles by TEM showed that all blank micelles were spherical in morphology 
and sizes ranged between 55 nm to 295 nm, where C16-(PEG2)6-LDV micelles had the 
largest sizes (figure 3.8).  This is likely due to the longer number of ethylene oxide units and 
subsequent increased repulsive forces resulting in a looser packing density, forming larger 
micelle structures [65].  Conversely, hydrophobic interactions of micelles with shorter 
hydrophilic head groups predominated, resulting in tighter packing of hydrophobic fatty acid 
chains, forming smaller micelles.  The size of blank liposomes was in the range of 92.51 ± 
0.29 nm to 102.73 ± 0.12 nm and the size of SLNs were smaller in the range of 78.46 ± 4.31 
nm to 86.93 ± 3.49 nm (table 3.2).  These results indicate that the sizes of blank micelles, 
liposomes and SLNs are in the ideal range for tumor targeting via the EPR effect.  The PDI 
values for liposomes and SLNs were ≤2, which indicates a narrow size distribution.  
The magnitude of the zeta potential provides an indication of the colloidal stability.  
Specifically, zeta potential values more positive than +30 mV or more negative than -30 mV 
will repel each other decreasing the tendency to flocculate, indicating good colloidal stability.   
For liposomes, the zeta potential values were negative ranging between -34.47 ± 0.25 mV 
and -39.47 ±1.33 mV.  The zeta potential values for SLNs ranged between -45.46 ± 19.90 
mV and -65.55 ± 8.36 mV.  The negative zeta potential values can be attributed to the 
charged carboxylate group of aspartic acid in the LDV peptide region, indicating good 






















Figure 3.4:  Critical micelle concentration plot of I3/I1 ratio of pyrene v/s concentration of 
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Figure 3.5:  Critical micelle concentration plot of I3/I1 ratio of pyrene v/s concentration of 
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Figure 3.6:  Critical micelle concentration plot of I3/I1 ratio of pyrene v/s concentration of 
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Table 3.1:  Critical micelle concentration values for LDV-targeted micelles (n=3) 
 
Peptide Amphiphile CMC (μM) 
C16-(PEG2)
2
-LDV  28.31 ± 3.85 
C16-(PEG2)
4
-LDV  23.68 ± 0.72 
C16-(PEG2)
6







































































Table 3.2:  Comparison of size, zeta potential and PDI of LDV-targeted blank micelles, blank 
liposomes and blank solid lipid nanoparticles (n=3) 
 
 
Nanocarrier Size (nm) Zeta potential (mV) PDI 
C16-(PEG2)2-LDV micelle 54 ± 4.90 ND ND 
C16-(PEG2)4-LDV micelle 55 ± 10.0 ND ND 
C16-(PEG2)6-LDV micelle 295 ± 65.0 ND ND 
C16-(PEG2)2-LDV liposome 97.32 ± 0.45 -39.47 ± 1.33 0.200 
C16-(PEG2)4-LDV liposome 92.51 ± 0.29 -34.47 ± 0.25 0.174 
C16-(PEG2)6-LDV liposome 102.73 ± 0.12 -35.33 ± 0.10 0.137 
C16-(PEG2)2-LDV SLN 78.46 ± 4.31 -45.46 ± 19.90 0.209 ± 0.004 
C16-(PEG2)4-LDV SLN 87.07 ± 1.79 -65.55 ± 8.363 0.207 ± 0.002 














Chapter 4: In Vitro Stability and Drug Release Characterization 
 
4.1 Stability of LDV-targeted Micelles, Liposomes and SLNs by FRET  
4.1.1 Introduction.  One of the major challenges with the use of nanocarriers, is  
their instability when administered systemically.  For example, micelles are known to 
disassemble when diluted below the CMC upon systemic administration.  Additionally, 
nanocarriers can destabilize and disrupt due to interactions with blood components, causing 
premature drug release and reduced anti-cancer efficacy.  Nanocarriers can be loaded with 
fluorescent dyes that are used to probe the stability upon dilution and under physiological 
conditions.  For example, Forster Resonance Energy Transfer (FRET) is a distance-dependent 
process where energy is transferred from an excited fluorophore (donor dye) to another 
fluorophore (acceptor dye) and has been used to probe the stability of various nanocarriers 
including polymeric micelles and liposomes [66, 67].  Specifically, donor and acceptor FRET 
dyes (DiO and Dil) can be loaded into the hydrophobic core of micelles, the bilayer of 
liposomes and the solid lipid core of SLNs.  Upon excitation of the donor dye, energy is 
transferred to the acceptor dye and energy is released at the emission wavelength of the 
acceptor molecules, due to the close proximity of the dyes within the hydrophobic regions of 
the nanocarriers.  Typically, energy transfer can only occur if the dyes are within 10 
angstroms of each other.  When nanocarriers are disrupted, the dyes are released and the 
larger distance between them results in a loss of energy transfer between donor and acceptor 
dyes.  High FRET efficiencies indicate the presence of physically stable nanocarriers and low 





































4.1.2 Materials.  PAs were synthesized as described in the section 2. (CA, USA).  
DPPC lipids and liposome extruder was purchased from Avanti polar lipids (AL, USA). 
Tripalmitin was purchased from Sigma-Aldrich (MO, USA).  FRET dyes 3,3′-
dioctadecyloxacarbocyanine perchlorate (DiO) and 1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate (Dil) were purchased from Invitrogen (Carlsbad 
CA, USA). Dialysis membranes MWCO 1000 Da were purchased from Spectrum 
Laboratories (Rancho Dominguez, CA, USA), Solvents including DCM, methanol, ethanol, 
N,N’-dimethyl formamide (DMF) and chloroform were purchased from fisherscientific 
(Pittsburg, PA). 
4.1.3 Methods.  FRET dyes DiO and Dil were loaded into micelles, liposomes and  
SLNs using the same methods for preparation of blank nanocarriers.  Table 4.1 summarizes 
the methods, compositions, lipid concentrations and drug loading of FRET dye-loaded 
nanocarriers. 
a) Preparation of FRET dye-loaded micelles.  FRET pair dyes DiO and Dil  
were loaded into micelles through the dialysis membrane technique.  PAs were mixed 
together with FRET dyes in DMF and left shaking in a water-bath at 50⁰C for approximately 
1 hour.  The mixture was then transferred into dialysis membrane tubing (MWCO 1000) and 
dialyzed against 1 liter of water, which was exchanged three times over 24 hours. After 
dialysis, micelle samples were removed by transferring into glass vials and covering with 
aluminum foil prior to characterization.  Micelles were prepared from all three PAs and each 
micelle composition was prepared in triplicates.   
b) Preparation of FRET dye-loaded liposomes.  Liposomes were prepared using the 
 thin-film hydration and extrusion method.  A mixture of DPPC, PA and FRET dyes were 
dissolved in chloroform: methanol = 2:1 (v/v) at a molar ratio of 1:0.5:0.02.  Organic solvents 
were evaporated to dryness under a stream of nitrogen gas and solvent traces were removed 
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by leaving the glass tubes under vacuum overnight.  The dried lipid film was then hydrated 
by the addition of aqueous solution at a temperature between 50⁰C to 55⁰C, followed by 
vortexing periodically for 30 minutes to detach any lipid from the glass surface.  Hydration 
was carried out in a water bath and the temperature was maintained above the main phase 
transition temperature (Tm) of lipids (41⁰C for DPPC).  This process resulted in the formation 
of MLVs, which were subjected to six freeze-thaw cycles with liquid nitrogen and heated DI 
water.  MLVs were downsized by extruding 21 times through 0.1µm-pore polycarbonate 
membrane filters.  Liposomes were prepared using all three PAs and each liposome 
composition was prepared in triplicates.  Following preparation, liposome suspensions were 
protected with aluminum foil prior to characterization. 
c) Preparation of FRET dye-loaded solid lipid nanoparticles. The NanoAssemblr  
(Benchtop, Precision NanoSystems Inc., Vancouver, Canada) was used to prepare SLNs by 
microfluidic mixing.  Specifically, a microfluidic cartridge comprising of moulded channels 
with staggered herringbone structures was used to formulate SLNs by mixing of the organic 
(tripalmitin and FRET dyes in ethanol) and aqueous (PA in water) phases at a molar ratio of 
1:0.5:0.02.  The organic and aqueous phases were pumped into two inlets of the microfluidic 
chip using disposable syringes and mixing was controlled by setting the FRR to 3:1 and the 
TFR to 15mL/min.  At all steps of preparation, the organic and aqueous phases were kept at 
75⁰C by keeping solutions in the oven and installing a heat block into the NanoAssemblr 
instrument.  Next, the mixture was collected from the NanoAssemblr and transferred into G2 
slide-A-Lyzer dialysis cassettes (MWCO 10,000) and dialyzed against DI water to remove 
traces of ethanol.  Specifically, the dialysis membrane was hydrated in DI water for 2 minutes 
prior to dialysis.  Then the dialysis cassette was stirred in DI water, which was exchanged 
every hour for 3 hours.  Post-dialysis, the sample was removed from the dialysis cassette and 
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used for further characterization.  SLNs were prepared using all three PAs and all SLN 
compositions were prepared in triplicate. 
d) Stability characterization.  The dilution stability of micelles, liposomes 
 and SLNs was determined by diluting 10-fold in aqueous solution or methanol (control) and 
recording the fluorescence spectra (excitation 484 nm, emission 495 nm to 600 nm) using a 
fluorescence spectrophotometer (Shimadzu Spectrofluorometer for micelles and liposomes 
and a SpectraMax M2 microplate reader for SLNs).  FRET ratios were calculated using 
fluorescence intensity values of dyes;  IDIL/(IDIL+IDIO), where lower ratios represent increased 
micelle, liposome or SLN disassembly.  For stability in serum, micelles, liposomes and SLNs 
were diluted 10-fold in human serum or in 0.1% triton X-100 (control) and the FRET ratios 
were calculated using the same method.  The results were plotted using GraphPad Prism 
software and a non-linear fit of FRET ratio’s was generated by least squares and the rate 
constants (K) were determined.  The rate constants were statistically compared using one-
way ANOVA followed by Tukey post-test. A p value <0.05 was considered statistically 




4.1.4   Results and discussion.  The effectiveness of nanocarriers for tumor targeting  
is dependent on the ability to remain intact before reaching the target tumor site.  Therefore, 
nanocarriers must remain intact and circulate in the blood for a sufficient amount of time to 
allow accumulation at the tumor site.  Specifically, premature drug release can occur when 
micelles are administered intravenously and diluted below the CMC.  Furthermore, 
nanocarriers are prone to protein adsorption, leading to opsonization and phagocytosis by 
macrophages of the RES in the blood circulation or in the liver and spleen.  Serum proteins 
can also partition into the nanocarriers, causing disruption and premature drug release.  
Therefore, for effective drug targeting and delivery to occur, nanocarriers must be able to 
withstand the effects of dilution and remain stable in the presence of serum.  FRET dyes were 
loaded into micelles, liposomes and SLNs and these nanocarriers were characterized for their 
ability to remain intact upon dilution and in the presence of serum.  When micelles, 
liposomes and SLNs were diluted in excess aqueous solution, the fluorescence spectrum 
remained unchanged, showing a major emission peak at 570 nm upon excitation at the 
appropriate wavelength (figures 4.4 to figure 4.24).  This indicates energy transfer due to the 
close proximity of dyes in the bilayer of liposomes and in the core of micelles and SLNs.  For 
all nanocarriers except C16-(PEG2)2-LDV micelles, FRET efficiencies remained high 
(≥0.85), indicating good stability upon dilution (table 4.2 and table 4.3).  When micelles, 
liposomes and SLNs were disrupted in methanol, FRET dyes were released and diffused 
apart, resulting in loss of energy transfer.  As a result, a shift in the emission peak from 570 
nm to 505 nm was observed.  When micelles, liposomes and SLNs were diluted in human 
serum, an increase in the fluorescence intensity at 505 nm and a decrease at 570 nm was 
observed over 8 hours, indicating nanocarrier disassembly or FRET dye molecule release 
over time (figure 4.25 to figure 4.45).  The rate of nanocarrier disassembly was the fastest for 
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micelles, followed by liposomes and SLNs, with rate constant values of 2.77 ± 0.39 hr-1, 0.61 
± 0.09 hr-1 and 0.20 ± 0.05 hr-1 respectively (table 4.5).  Upon statistical analysis of rate 
constants, there were significant differences between nanocarriers (p<0.0001).  The Tukey 
test revealed a significant difference between the rate constants of micelles vs liposomes 
(p<0.0001) and micelles vs SLNs (p<0.0001).  However, there was no significant difference 
between the rate constants of liposomes and SLNs (p=0.16).  For micelles in serum, the 
FRET efficiency decreased from 1 to 0.51 over 1 hour.  At 3 hours, the FRET ratio (≈0.42) 
reached a plateau, indicating complete micelle disassembly or FRET molecule release at this 
time.  For liposomes in serum, the decrease in FRET efficiency over 1 hour was less 
compared to micelles (1 to 0.74) and the FRET ratio plateaued at 5 hours (≈0.45).  Compared 
to micelles and liposomes, SLNs were the most stable in serum with only a small decrease in 
the FRET ratio from 1 to 0.88 over 1 hour and a steady decrease to ≈0.63 over 8 hours.  
When micelles, liposomes and SLNs were disrupted in triton X-100, a shift in the emission 
peak from 570 nm to 505 nm was observed, indicating complete disassembly or FRET 
molecule release.  Overall, the results demonstrate that micelles were more prone to 
destabilization in the presence of serum compared to liposomes and SLNs.  Micelles formed 
from low molecular weight amphiphiles are dynamic structures and the continuous exchange 
of amphiphiles between micelles contributes to poor stability.  However, compared to 
micelles, the phospholipid bilayer of liposomes imparts increased rigidity and improved 
mechanical properties, leading to increased retention of FRET dye molecules and increased 
resistance to disruption by serum proteins.  SLNs demonstrated higher stability over micelles 
and liposomes, which is likely due to rigid solid nature of the lipid core, which affords 





Figure 4.5: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)2-LDV micelles 








Figure 4.7:  Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)4-LDV micelles 
diluted 10-fold in aqueous solution  
 
 




Figure 4.9:  Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)6-LDV micelles 
diluted10-fold in aqueous solution  
 
 















Figure 4.11:  Normalized FRET efficiency of LDV-targeted liposomes when diluted 10-fold 









Figure 4.12:  Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)2-LDV 
liposomes diluted 10-fold in aqueous solution  
 
 




Figure 4.14: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)4-LDV 
liposomes diluted 10-fold in aqueous solution  
 
 




Figure 4.16:  Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)6-LDV 
liposomes diluted 10-fold in aqueous solution  
 
 
















Figure 4.18:  Normalized FRET efficiency of LDV-targeted solid lipid nanoparticles when 









Figure 4.19:  Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)2-LDV solid 
lipid nanoparticles diluted 10-fold in aqueous solution  
 
 
Figure 4.20:  Emission spectra of Dil + DiO C16-(PEG2)2-LDV solid lipid nanoparticles 




Figure 4.21:  Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)4-LDV solid 
lipid nanoparticles diluted 10-fold in aqueous solution  
 
 
Figure 4.22:  Emission spectra of Dil + DiO C16-(PEG2)4-LDV solid lipid nanoparticles 




Figure 4.23:  Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)6-LDV solid 
lipid nanoparticles diluted 10-fold in aqueous solution  
 
 
Figure 4.24: Emission spectra of Dil + DiO C16-(PEG2)6-LDV solid lipid nanoparticles 










Table 4.2:  Normalized FRET efficiencies of DiO + Dil dye-loaded micelles, liposomes and 




C16-(PEG2)2-LDV micelles 0.68 ± 0.01 
C16-(PEG2)4-LDV micelles 0.88 ±  0.02 
C16-(PEG2)6-LDV micelles 0.87 ±  0.02 
C16-(PEG2)2-LDV liposomes 0.85 ± 0.01 
C16-(PEG2)4-LDV liposomes 0.86 ±  0.00 
C16-(PEG2)6-LDV liposomes 0.85 ± 0.01 
C16-(PEG2)2-LDV SLNs 0.95 ± 0.01 
C16-(PEG2)4-LDV SLNs 0.99 ± 0.00 



















Table 4.3:  Average normalized FRET efficiencies of DiO + Dil FRET dye-loaded micelles, 
liposomes and solid lipid nanoparticles when diluted 10-fold in aqueous solution (n=3) 
 
Nanocarrier Average	Normalized	FRET	efficiency	at	1	hour	
C16-(PEG2)n-LDV micelles 0.81 ± 0.11 
C16-(PEG2)n-LDV liposomes 0.85 ± 0.01 





















Figure 4.25:  Normalized FRET efficiency of LDV-targeted micelles when diluted 10-fold in 











Figure 4.26: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)2-LDV 










Figure 4.28: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)4-LDV 











Figure 4.30:  Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)6-LDV 























Figure 4.32:  Normalized FRET efficiency of LDV-targeted liposomes when diluted 10-fold 
















Figure 4.33:  Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)2-LDV 













Figure 4.35. Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)4-LDV 










Figure 4.37:  Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)6-LDV 
























Figure 4.39:  Normalized FRET efficiency of LDV-targeted solid lipid nanoparticles when 




















Figure 4.40: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)2-LDV solid 





Figure 4.41:  Emission spectra of Dil + DiO C16-(PEG2)2-LDV solid lipid nanoparticles 





Figure 4.42: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)4-LDV solid 





Figure 4.43:  Emission spectra of Dil + DiO C16-(PEG2)4-LDV solid lipid nanoparticles 






Figure 4.44:  Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)6-LDV solid 






Figure 4.45:  Emission spectra of Dil + DiO C16-(PEG2)6-LDV solid lipid nanoparticles 










Table 4.4:  Normalized FRET efficiencies of all DiO + Dil FRET dye-loaded micelles, 
liposomes and solid lipid nanoparticles in human serum (n=3) 
 
Nanocarrier Normalized FRET  
efficiency n serum   
C16-(PEG2)2-LDV micelles 0.51 ± 0.01 
C16-(PEG2)4-LDV micelles 0.47 ± 0.01 
C16-(PEG2)6-LDV micelles 0.54 ± 0.02 
C16-(PEG2)2-LDV liposomes 0.79 ± 0.01 
C16-(PEG2)4-LDV liposomes 0.69 ± 0.02 
C16-(PEG2)6-LDV liposomes 0.75 ± 0.01 
C16-(PEG2)2-LDV SLNs 0.89 ± 0.03 
C16-(PEG2)4-LDV SLNs 0.90 ± 0.01 


























Table 4.5:  Average normalized FRET efficiencies and rate constants of DiO + Dil FRET 
dye-loaded micelles, liposomes and solid lipid nanoparticles (n=3) 
 
Nanocarrier Normalized FRET 
efficiency in serum at 1 
hour  
Rate constant K (1/hr) 
C16-(PEG2)n-LDV micelles 0.51 ± 0.04 2.77 ± 0.39 
C16-(PEG2)n-LDV liposomes 0.74 ± 0.05 0.61 ± 0.09 



























4.2  In Vitro Release of Paclitaxel-Loaded Targeted Micelles, Liposomes and SLNs 
 
4.2.1 Introduction.  Paclitaxel was loaded into micelles, liposomes and SLNs and 
 characterized for size, morphology, charge, drug loading efficiency and drug release.  
Paclitaxel is a natural anti-cancer agent extracted from taxus with broad spectrum anti-tumor 
effects.  Paclitaxel is a widely used therapeutic agent that works through cell tubulin 
polymerization and inhibition of depolymerization, preventing the formation of normal 
mitotic apparatus.  However, there are significant challenges associated with the formulation 
and administration of paclitaxel due to poor aqueous solubility (≤ 0.3µg/mL), requiring the 
use of additional solvents and excipients for effective administration.  For example, Taxol is 
a commercialized FDA approved product comprising of paclitaxel dissolved in 
polyethoxylated castor oil (Cremophor EL) and dehydrated ethanol, which is then diluted in 
0.9% normal saline prior to intravenous administration.  Unfortunately, Taxol has several 
limitations, including precipitation upon dilution and severe side effects due to cremophor 
EL, resulting in reduced therapeutic efficacy.  To eliminate such side effects and improve 
drug solubility, paclitaxel can be loaded into micelles, liposomes and SLNs.  
4.2.2 Materials.  PAs were synthesized as described in section 2. (CA, USA)  
and GenScript (Piscataway, NJ). DPPC lipids and liposome extruder was purchased from 
Avanti polar lipids (AL, USA). Solvents including DCM, methanol, ethanol and chloroform 
were purchased from fisherscientific (Pittsburg, PA). Paclitaxel was purchased from LC 
laboratories. Tripalmitin was purchased from Sigma-Aldrich (MO, USA). Float-A-Lyzer G2 
dialysis tubes (MWCO 10,000) were purchased from Spectrum Laboratories (Rancho 
Dominguez, CA). Pierce Slide-A-Lyzer G2 dialysis cassettes (MWCO 10,000) were 





a) Preparation of paclitaxel-loaded micelles, liposomes and SLNs.  Paclitaxel- 
loaded nanocarriers (PTX-liposomes, PTX-micelles and PTX-SLNs) were prepared using 
similar methods as for blank nanocarriers (table 4.6). For PTX-liposomes, the hydrophobic 
components, DPPC, PA and paclitaxel were dissolved in chloroform: methanol = 2:1 (v/v).   
Organic solvents were evaporated to dryness under a stream of nitrogen gas and solvent 
traces were removed by leaving the glass tubes under vacuum overnight.  The dried lipid film 
was then hydrated by the addition of DI water at a temperature between 50⁰C to 55⁰C, 
followed by vortexing periodically for 30 minutes to detach any lipid from the glass surface. 
Hydration was carried out in a water bath and the temperature was maintained above the 
main phase transition temperature (Tm) of lipids (41⁰C for DPPC).  This process resulted in 
the formation of MLVs, which were subjected to six freeze-thaw cycles with liquid nitrogen 
and heated DI water.  MLVs were downsized by extruding 21 times each through 0.4µm, 
0.2µm, and 0.1µm-pore polycarbonate filters to produce SUVs.  Paclitaxel was loaded into 
micelles using the solvent evaporation method.  In a glass tube, PAs and paclitaxel were 
dissolved in methanol. Then methanol was evaporated under nitrogen gas and solvent traces 
were removed under vacuum overnight.  Next, the dry lipid film was hydrated by the addition 
of DI water at a temperature between 50⁰C to 55⁰C, followed by vortexing and sonicating 
periodically for 30 minutes to detach any lipid from the glass surface.  The resulting mixture 
was then centrifuged at 3000 rpm for 1 hour to remove excess paclitaxel and yield a clear 
micelle solution. The NanoAsssmblr (Benchtop, Precision NanoSystems Inc., Vancouver, 
Canada) was used to prepare PTX-SLNs by microfluidic mixing.  Specifically, a microfluidic 
cartridge comprising of moulded channels with staggered herringbone structures was used to 
formulate PTX-SLNs by mixing of the organic (tripalmitin and paclitaxel in ethanol) and 
aqueous (PA in water) phases.  The organic and aqueous phases were pumped into two inlets 
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of the microfluidic chip using disposable syringes and mixing was controlled by setting the 
FRR to 3:1 and the TFR to 15 mL/min.  At all steps of preparation, the organic and aqueous 
phases were kept at 75⁰C by keeping solutions in the oven and installing a heat block into the 
NanoAssemblr instrument.  Next, the mixture was collected from the NanoAssemblr and 
transferred into G2 slide-A-Lyzer dialysis cassettes (MWCO 10,000) and dialyzed against 
water to remove traces of ethanol.  Specifically, the dialysis membrane was hydrated in DI 
water for 2 minutes prior to insertion of SLN sample.  Then the dialysis cassette was stirred 
in DI water, which was exchanged every hour for 3 hours.  PTX micelles, PTX-liposomes 
and PTX SLNs were prepared using all three PAs and each composition was prepared in 
triplicates.  
b) Paclitaxel loading efficiency for micelles, liposomes and SLNs.  Samples were  
prepared by diluting nanocarriers 10-fold in methanol and vortexing to ensure complete 
solubilization of lipids and paclitaxel.  Paclitaxel concentration was determined using 
isocratic RP-HPLC (HPLC Agilent 1200 series, Agilent Technologies Inc.) using a C18 
column (Agilent 4.6 mm x 250, 5µm) at 25⁰C.  The mobile phase consisted of 
acetonitrile/water (70/30, v/v) at a flow rate of 1.0 mL/min.  Paclitaxel was detected with 
ultraviolet (UV) detection at 227 nm using 20µl injection volumes.  A calibration curve was 
generated by plotting known concentrations of paclitaxel against peak area using a series of 
standards ranging between 1µg/ml to 100 µg/ml. The standard curve was used to determine 
the concentration of paclitaxel in PTX-micelles, PTX-liposomes and PTX-SLNs.  Drug 
Loading Content (DLC) and Drug Loading Efficiency (DLE) was determined using equations 
4.1 and 4.2: 
Equation 4.1 𝐷𝐿(%) = QRSTUV	SL	WBX	YU	UMUSZM[[Y\[
QRSTUV	SL	WBX	]SM^\^	UMUSZM[[Y\[_	
 x 100 
 





c) Determination of size, PDI, zeta potential and morphology.  The size, PDI and  
zeta potential of PTX-liposomes and PTX-SLNs were determined using DLS on the Zetasizer 
ZS 90 (Malvern Instruments, Ltd., Malvern, UK).  For nanocarrier size, PDI and zeta 
potential, measurements were taken in a disposable microcuvette at 25°C.  For each sample, 
measurements were taken three times. The morphology and size of PTX-micelles, PTX-
liposomes and PTX-SLNs was determined by Nanoimaging Services Inc (San Diego, CA) 
using a FEI Tecnai T12 electron microscope (serial number D1100), operating at 120keV 
equipped with a FEI Eagle 4k x 4k CCD camera.  For Electron Microscope (EM) grid 
preparation, 3µl of each nanocarrier sample was applied to a cleaned 400-mesh copper grid 
and blotted away with filter paper.  Next, vitrification was carried out in liquid ethane and 
these vitreous ice grids were transferred into the EM using a cryostage that maintains the 
grids at a temperature below -170⁰C.  Images of each grid were acquired at multiple scales to 
assess the overall distribution of the specimen. After identifying potentially suitable target 
areas for imaging at lower magnifications, high magnification images were acquired at 
nominal magnifications of 110,000x (0.10 nm/pixel), 52,000x (0.21 nm/pixel) and 21,000x 
(0.50 nm/pixel). The images were acquired at a nominal underfocus of -5.0μm to -1.0μm and 





d) Determination of in vitro drug release. Dialysis tubes (Float-A-Lyzer G2,  
MWCO 10,000) were used to determine in vitro release profiles of PTX-micelles, PTX-
liposomes and PTX-SLNs.  Dialysis devices containing 1mL of nanocarrier sample was 
placed into 4 liters of DI water at 37⁰C and magnetically stirred.  At predetermined time 
points up to 24 hours, aliquots (20 µl) of nanocarrier sample were removed from the dialysis 
tube and paclitaxel content was analyzed using HPLC as described above. The release 
profiles were analyzed using non-linear regression analysis performed by GraphPad Prism 
software. The release rate constants and time to release 50% of drug (t50%) from micelles, 
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liposomes and SLNs were determined and statistically compared using one-way ANOVA 
followed by the Tukey multiple comparison test. A P-value of <0.05 was considered 
statistically significant. 
4.2.4 Results and discussion. 
a) Physicochemical characterization of paclitaxel-loaded nanocarriers. The 
physicochemical characterization and drug loading of PTX-micelles, PTX-liposomes and 
PTX-SLNs such as hydrodynamic size, zeta potential and DLC are summarized in tables 4.7 
and 4.8.  DLS results showed that there was no significant difference between the 
hydrodynamic sizes of all PTX-liposomes and these ranged between 117.27 ± 8.08 nm and 
129.00 ± 8.32 nm.  The hydrodynamic sizes of all PTX-SLNs was also similar and ranged 
between 74.40 ± 4.39 nm and 84.4 ± 2.77 nm.  The hydrodynamic sizes of micelles could not 
be determined by DLS, therefore cryoTEM was used to determine the size and morphology 
of PTX-micelles (figure 4.46).  For these micelles, the images showed roughly round 
particles between 6 nm to 12 nm, which are significantly smaller than the sizes of blank 
micelles characterized by TEM.  This effect of size reduction of drug-loaded micelles 
compared to blank micelles has previously been observed and may be explained by the 
intermolecular interactions between paclitaxel and the core of the micelle [68, 69].  Paclitaxel 
is physically incorporated in the core of micelles, enhancing the hydrophobic interactions 
resulting in the formation of smaller particles.  CryoTEM imaging of PTX-liposomes 
revealed unilamellar particles with rounded to angular appearance, ranging between 48-145 
nm in their longest dimension.  PTX-liposomes had an interior density that was similar to the 
density of the surrounding aqueous medium, indicating the presence of a hydrophilic core 
that is commonly found in liposomes.  The outer layer of the particles resembled a lipid 
bilayer which has a thickness of 6 to 7.5 nm in width.  The sample also contained many short 
narrow particles ranging between 20 to 40 nm in length and 5 to 7 nm in width as well as 
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some round to oblong particles that were 20 to 40 nm in their longest dimension, which are 
likely different views of lipid-based, disk-shaped particles.  PTX-SLNs were also imaged and 
revealed particles ranging from 10 to 120 nm that were mostly round to oblong and  
occasionally angular in appearance. Particles had an interior density that was slightly denser 
than the surrounding aqueous solution, indicating the presence of a lipid core.  The sample 
also contained a few short narrow particles with a length of 12 to 30 nm and a width of 6 to 
14 nm.  In general, DLS results showed that sizes of PTX-SLNs were smaller than PTX-
liposomes (80.53 ± 5.37 nm vs 123.31 ± 5.87 nm) and PDI values were ≤0.2.  CryoTEM 
results confirmed the smaller size range of PTX-SLNs (10-120 nm) compared to PTX-
liposomes (48-145 nm) and PTX-micelles had the smallest sizes between 6 to 12 nm.  
Although the smaller sizes of PTX-micelles may increase uptake and tumor penetration, the 
size of these micelles fall outside the ideal nanocarrier size range (10-100 nm), where sizes 
smaller than 10 nm may be easily excreted by the kidneys. PTX-liposomes and PTX-SLNs 
showed ideal size ranges.  Zeta potential values ranged between -23.61 ± 10.23 mV and -
51.65 ± 10.82 mV for PTX-micelles, PTX-liposomes and PTX-SLNs, which is attributed to 
the carboxylate group present in the peptide. The highly negative charge of these nanocarriers 
provides good colloidal stability and may help to prevent interactions with opsonins [70, 71].  
However, negatively charged particles may prevent efficient cellular uptake due to the 
negatively charged cellular membrane[72, 73].   
b) Paclitaxel loading efficiency of micelles, liposomes and SLNs.  Drug loading  
into micelles depend upon the partitioning of lipophilic drug molecules into the micelle core 
and the extent to which this occurs can be described by the partition coefficient.  In particular 
an increase in the length of the hydrophobic region will improve the partitioning behavior of 
hydrophobic drugs into the micelle core. There are several factors that affect the drug loading 
efficiency of micelles, which include the compatibility of the drug with the core forming 
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component of the micelle, the hydrophobicity, nature and length of the core-forming segment, 
the length and nature of the corona-forming component, the interactions between the drug 
and core and the method of micelle preparation.  In general, the larger the hydrophobic 
segment, the larger the core for increased drug entrapment.  An increase in the hydrophilic 
segment results in an increase in the CMC and reduced drug loading [74-76].   For all PTX-
micelles, the DLC and DLE was low: ranging between 1.28 ± 0.07 wt % to 2.11± 0.46 wt % 
and 12.88 ± 0.75 % to 21.13 ± 4.59 % (table 4.7) which is typically seen for micelles with 
DLC’s ranging between 1-20 wt% [77].  The highest DLC was achieved for C16-(PEG2)2-
LDV PTX-micelles, which is likely due to the increased hydrophobicity and lower CMC 
value.  Like micelles, efficient drug loading is highly dependent on the compatibility of drug 
molecules with the hydrophobic segment of the nanocarrier.  For efficient drug loading into 
liposomes, the drug must be significantly hydrophobic with high log P values  
(≥ 3) for partitioning into the hydrophobic region of the phospholipid bilayers.  Paclitaxel has 
a log P value of 3.6 and can be loaded into liposomes, which has been demonstrated through 
the development of Lipusu currently on the market and LEP-ETU currently undergoing 
clinical trials [38, 78].  However, the bulky and asymmetric nature of paclitaxel makes 
liposomal drug loading challenging and often leads to paclitaxel leakage or precipitation 
immediately after preparation or during storage.  Consequently, it was shown that that only 
≤3.3 mol% can be loaded into lipid bilayers, resulting in poor drug loading efficiency [79].  
In the initial studies, paclitaxel was loaded into liposomes at similar lipid concentrations to 
micelles (1mg/mL), however these vesicles were unstable and aggregated, which was likely 
due to an insufficient amount of lipid available to effectively retain paclitaxel in the 
phospholipid bilayer. Furthermore, initial drug loading at 10 wt% resulted in destabilization 
of vesicles, indicating that an optimal balance between lipid concentration and paclitaxel 
concentration was required to produce stable vesicles.  Subsequently, stable PTX-liposomes 
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were produced when prepared at higher lipid concentrations (15 mg/mL) and lower initial 
DLC at 1 wt%, which resulted in drug loading capacities ranging between 0.83 ± 0.41 wt% to 
1.00 ± 0.01 wt% and DLE’s ranging between 63.93 ± 31.85 % and 106.51 ± 0.68 % (table 
4.7).  Compared to PTX-micelles and PTX-liposomes, PTX-SLNs demonstrated the highest 
DLC and DLE with values ranging between 7.14 ± 0.17 wt% to 7.91 ± 0.87 wt% and 71.49 ± 
1.66 % to 79.15 ± 8.65 % respectively (table 4.7).  This is likely due to the use of high 
melting point triglycerides that help to increase paclitaxel incorporation and retention inside 
the lipid matrix.  These results showed that paclitaxel was efficiently loaded into PTX-
micelles, PTX-liposomes and PTX-SLNs and the variation in DLE’s may be due to 
nanocarrier structure, lipid compatibility with drug and methods used for producing 
nanocarriers. 
a) Determination of in vitro drug release.  Upon systemic administration,  
nanocarriers must extravasate into the tumor and either undergo interstitial drug release or 
intracellular release. Therefore, nanocarriers must be designed to demonstrate drug release in 
a controlled sustained release manner for enabling drug accumulation in the tumor.  For 
example, Doxil is a liposomal formulation encapsulating doxorubicin and delivers 10 to 15 
times more drug to the tumor compared to free doxorubicin.  However, the bioavailability of 
Doxil is only 40 to 50% due to slow release, indicating that the excessive stability of this 
formulation is problematic [80].  Conversely, a polymeric micelle formulation Genexol-PM 
encapsulating paclitaxel has been shown to be too unstable upon systemic administration, 
where paclitaxel partitions out of the micelle and interacts with serum proteins, resulting in 
premature drug release before reaching the target site [80].  Therefore, the key challenge is to 
develop nanocarriers that maintain stability before reaching the tumor whilst allowing for 
efficient release when reaching the tumor site.  In this study, the in vitro release profiles of 
PTX-micelles, PTX-liposomes and PTX-SLNs were compared to provide an indication of the 
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ability of these nanocarriers to retain drug under sink conditions.  Compared to PTX-
liposomes and PTX-SLNs, the release rate of paclitaxel from micelles was the fastest with 
≥95% of the drug being released over 4 hours (figure 4.49). This is likely due to the dynamic 
nature of micelles, disassembly of micelles or rapid diffusion of paclitaxel from the micelles 
under sink conditions.  Paclitaxel was released from liposomes at a slower rate than PTX-
micelles, with ≈20% of drug release by 4 hours and ≈60% released over 24 hours (figure 
4.50).  These results demonstrate that PTX-liposomes have improved drug retention 
properties over PTX-micelles, presumably due to the more rigid and mechanical structure of 
the phospholipid bilayer membrane.  All PTX-SLNs exhibited the slowest release rate 
compared to PTX-micelles and PTX-liposomes, where only 3-13% of PTX was released over 
4 hours and 16-40% released over 24 hours (figure 4.51).  These results showed a significant 
increase in drug retention in PTX-SLNs compared to PTX-micelles and PTX-liposomes, 
which is likely due to the core-forming high melting point triglyceride, which may have 
significantly decreased the mobility of paclitaxel molecules within the lipid core, reducing 
drug leakage [81].  In contrast, PTX-liposomes are formed from DPPC lipids which have a 
gel-to-liquid phase transition temperature (41⁰C) that is close to the body temperature, 
increasing the membrane fluidity and probability of paclitaxel molecules leaking out of the 
phospholipid bilayer membrane [82, 83].  The differences in release rates between PTX-
micelles, PTX-liposomes and PTX-SLNs are described by release rate constants and t50% 
values presented in table 4.8.  The release rate constants were the highest for PTX-micelles 
compared with PTX-liposomes and PTX-SLNs (0.80 ± 0.09/hr vs 0.08 ± 0.03/hr and 
0.02±0.01/hr).  One-way ANOVA results showed that there was a significant difference 
between the t50% values of PTX-micelles, PTX-liposomes and PTX-SLNs (p=0.03).  
Specifically, the t50% values for PTX-micelles were significantly lower compared to PTX-
liposomes and PTX-SLNs.  The Tukey test revealed a significant difference with PTX-
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micelles vs PTX-SLNs (p=0.03) and PTX-liposomes vs PTX-SLNs (p=0.06).  However, 







Figure 4.46: CryoTEM image of paclitaxel-loaded LDV targeted-micelles at a magnification 
of 52,000x. Observed in the sample are small particles that vary in size (yellow arrows), and 


















Figure 4.47:  CryoTEM image of paclitaxel-loaded LDV-targeted liposomes at a 
magnification of 52,000x. Observed in the sample are unilamellar particles with a round 
angular appearance and with an interior density similar to that of the surrounding aqueous 
solution (red arrow); elongated particles (cyan arrow); round to elongated faint particles 









Figure 4.48:  CryoTEM image of paclitaxel-loaded LDV-targeted solid lipid nanoparticles at 
a magnification of 52,000x. Observed in the sample are particles of various sizes that have an 
interior density that is slightly more dense than that of the surrounding buffer and are roughly 
round (orange arrow); angular or oblong in shape (purple in shape); small and elongated 





Figure 4.49: In vitro release profiles of paclitaxel-loaded LDV-targeted micelles in aqueous 




















Figure 4.51: In vitro release profiles of paclitaxel-loaded LDV-targeted solid lipid 









Figure 4.52: Summary of in vitro release profiles of paclitaxel-loaded LDV targeted micelles, 





















Table 4.8: Average size, DLC, DLE, rate constants and t50% values for paclitaxel-loaded 
micelles, liposomes and solid lipid nanoparticles (n=3
Nanocarrier DLC (%) DLE (%) Size (nm) Rate constant  
K (1/hr) 
  t50% 
PTX-micelles 1.70 ± 0.41 17.06 ± 4.12 - 0.80 ± 0.09 0.87 ± 0.10 
PTX-liposomes 0.92 ± 0.08 80.82 ± 22.61 123.31 ± 5.98 0.08 ± 0.03 9.15 ± 3.12 
PTX-SLN 7.44 ± 0.41 74.39 ± 4.15 80.53 ± 5.37 0.02 ± 0.01 51.41 ± 30.99 
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4.3 Spray Drying of Paclitaxel-loaded LDV Targeted Micelles, Liposomes and SLNs 
4.3.1 Introduction.  One of the challenges faced with lipid-based nanocarriers is 
 their relative instability in aqueous dispersions.  Lipid nanocarriers can undergo physical and 
chemical degradation, resulting in decreased safety and loss of therapeutic efficacy.  
Chemical degradation can occur through the oxidation of fatty acid chains and the hydrolysis 
of ester bonds, resulting in the generation of free fatty acids, lysophospholipids and 
phospholgycerol compounds.  Physical instability occurs through vesicle fusion, aggregation 
and drug leakage [84].  These factors combined affect the quality of the final product, 
resulting in poor therapeutic efficacy and safety concerns.  For example, commercially 
available liposome products such as DOXIL are known to become unstable in solution, 
where drug leakage and liposome aggregation occurs [85].  To overcome these obstacles, 
aqueous dispersions of nanocarriers can be converted into a dry powder which can be stored 
over a long period of time but can be reconstituted at the time of administration.  As a result, 
stabilization is achieved by reducing the water content and the shelf-life is increased.  
Currently, lyophilization or freeze-drying are the most common methods for drying 
pharmaceutical products.  Freeze-drying involves the freezing of nanocarriers in aqueous 
solution followed by the removal of water from frozen samples by sublimation under 
vacuum.  However, during this process, the nanoparticles are subjected to freezing and drying 
stresses, which may result in nanocarrier destabilization.  For example, freezing can cause the 
disruption of liposome bilayer membrane structure due to the liquid-ice interface resulting in 
aggregation and vesicle fusion [86].  Furthermore, freeze-drying requires expensive 
equipment and may take several days to complete.  To overcome the limitations faced with 
freeze-drying, spray drying can be used to convert lipid-based nanocarriers into dry powders 
using a single step.  Spray drying is carried out through three stages, namely atomization, 
dehydration and powder collection.  Initially, the feedstock solution which is the nanocarrier 
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in aqueous solution is atomized into a hot drying gas such as nitrogen.  Atomization involves 
the application of an energy source that acts on a bulk liquid, resulting in the liquid break up 
into individual spray droplets.  Following atomization, microparticle formation occurs 
through the conversion of atomized spray droplets into solid particles.  The solid particles are 
then separated from the process gas stream using a cyclone and this principle is based on the 
density difference between the particle and gas.  During the spray drying process, heat and 
high shearing forces can result in the degradation of lipid components, therefore optimization 
of formulation and process parameters is critical to maintain the integrity of nanocarriers 
during spray drying.  For example, carbohydrate excipients such as mannitol, sucrose or 
trehalose are added into the feed to serve as bulking agents or protectants that result in the 
formation of microparticles embedded with nanocarriers [78, 87].  Other excipients such as 
amino acids and peptide sequences have also proved useful in spray drying by protecting 
against thermal stresses and denaturation, stabilization against aggregation and oxidation and 
reducing the hygroscopicity of various formulations [88]. For example, L-leucine has been 
used as an excipient for spray drying with lipid-based nanocarriers, due to hydrophobic and 
surfactant-like properties that enable migration to the surface of particles during the drying 
process, resulting in deaggregation and stabilization of particles [89-91]. In this study, 
selected PTX-micelles, PTX-liposomes and PTX-SLNs were spray dried with trehalose or a 








4.3.2 Materials.  PAs were synthesized at GenScript (Piscataway, NJ). DPPC 
 lipids and liposome extruder were purchased from Avanti polar lipids (AL, USA). Solvents 
including DCM, methanol, ethanol and chloroform were purchased from fisherscientific 
(Pittsburg, PA). Paclitaxel was purchased from LC laboratories. Tripalmitin and D-(+)-
Trehalose Dihydrate was purchased from Sigma-Aldrich (MO, USA). Pierce Slide-A-Lyzer 
G2 dialysis cassettes (MWCO 10,000) were purchased from VWR (CA, USA). L-leucine, 
aluminum stubs and carbon adhesive tapes were provided by AstraZeneca (SSF, USA). 
4.3.3 Methods. 
a) Spray drying of paclitaxel-loaded micelles, liposomes and SLNs. Initially, one of  
each type of nanocarrier was selected to determine the feasibility for spray drying. Upon 
evaluation, PTX-micelles formed from C16-(PEG2)4-LDV PAs were chosen since this 
nanocarrier has the lowest CMC value, small size and suitable water solubility for 
formulation preparation.  PTX-liposomes and PTX-SLNs formed from C16-(PEG2)4-LDV 
PAs were then selected for spray drying for direct comparison.  PTX-micelles, PTX-
liposomes and PTX-SLNs were prepared using the cosolvent evaporation method, thin-film 
hydration/extrusion method and microfluidic technology as previously described.  To 
determine which excipients are required to form stable nanocarriers upon spray drying, 
nanocarriers were spray dried in trehalose only or in a mixture of trehalose and l-leucine.  For 
feedstock preparation, 50mg of PTX-micelles, PTX-liposomes and PTX-SLNs were mixed 
with excipients (trehalose, L-leucine) dissolved in water at 2.5 wt% (table 4.9) and the total 
feedstock concentration was 20 mg/ml. The feedstock solution was then spray dried using a 
custom designed small-scale pharmaceutical spray dryer.  The dryer inlet temperature was 
maintained at 60°C; the dryer outlet temperature was maintained at 50°C. The drying gas 
flow rate was maintained at 850 slpm (standard liters per minute) with an atomization gas 
flow rate of 15 slpm. The collector jacket temperature and the cyclone jacket temperatures 
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were maintained at 50⁰C. The feedstock solution was fed into the spray dryer at rate of 
3 mL/min, which resulted in the deposition of spray dried material in a collector.  Next, the 
collector containing the spray dried powders was transferred into a glove box and the 
powders were then subsequently transferred into glass sample jars using a spatula.  The tare 
and gross weights of the collector and sample jars were then recorded and the production 
yield was calculated from the mass ratio of the collected powders to the total solid in the 
feed.  Sample handling was performed in a glove box with constant flushing of nitrogen.  
Prior to characterization, spray dried powders were kept in a dry box at low relative humidity 
(≤5%). 
b) Moisture content of spray dried powders.  The residual moisture content of all  
spray-dried powders were determined by the oven vaporizer Karl Fisher coulometric titration 
method using a Metrohm 874 oven sample processor (Switzerland). The oven temperature 
was set to 150⁰C and the gas flow to 75mL/min.  Samples were prepared by weighing out 
approximately 15mg of spray-dried powder into vials and sealed with caps.  Blank samples 
were also prepared by sealing an empty vial.  All samples were prepared in triplicate and 
analyzed using Tiamo 2.5 software. The moisture content was determined using the equation 
4.3. 
 










c) Differential Scanning Calorimetry (DSC). DSC measurements for all spray-dried  
powders were performed using a differential scanning calorimeter (DSC Q2000 TA, USA). 
Approximately 15mg of spray dried powder was loaded into an aluminum pan and 
hermetically sealed. The sample was heated at the scanning rate of 2°C/min to 150⁰C in a 
nitrogen atmosphere.  All samples were prepared in triplicate and analyzed using the TA 
instrument explorer Qseries software. 
d) Morphology of spray dried powders.  The morphology of spray-dried powders  
were evaluated using Scanning Electron Microscopy (SEM).  Sample preparation was carried 
out in a glove box under constant flushing with nitrogen and the relative humidity was kept 
below 5%.  Spray-dried powders were deposited onto an aluminum stub coated with 
conductive carbon tape. The aluminum stubs coated with sample were then sputter coated 
with gold-palladium for 60 seconds under high vacuum.  SEM imaging was performed using 
a JSM-IT100 microscope (JOEL Ltd., USA), operating at an acceleration voltage of 20 kV. 
e) Reconstitution and characterization of paclitaxel-loaded nanocarriers.  Spray 
dried powders were reconstituted with purified water and agitated for approximately 5 
minutes by hand until all the powder had dissolved.  The final lipid concentration upon 
reconstitution was 0.5 mg/mL.  Following reconstitution, the size, PDI and charge were 
characterized using the mobius zeta Potential and DLS detector (Wyatt, CA, USA).  The 
paclitaxel content was determined using the HPLC method previously described. 
f) Determination of stability.  The stability of paclitaxel-loaded nanocarriers before 
 and after spray drying was carried out by determination of size, PDI and paclitaxel content 
over 7 days at room temperature and at 4⁰C.  The size and PDI was determined using the 
mobius zeta Potential and DLS detector (Wyatt, CA, USA).  Paclitaxel content was 







Table 4.9:  Composition of spray dried formulations 
Name of formulation  Component (wt%) 
PTX-micelles/trehalose nanocarrier (2.5 wt%) 
 
trehalose (97.5 wt%)  
PTX-liposomes/trehalose nanocarrier (2.5 wt%) 
 
trehalose (97.5 wt%)  
PTX-SLN/trehalose nanocarrier (2.5 wt%) 
 
trehalose (97.5 wt %)  
PTX-micelles/trehalose/leucine nanocarrier (2.5 wt%) 
 
trehalose (77.5 wt%) 
 
leucine (20 wt%)  
PTX-liposomes/trehalose/leucine nanocarrier (2.5 wt%) 
 trehalose (77.5 wt%) 
 
Leucine (20 wt%)  
PTX-SLN/trehalose/leucine nanocarrier (2.5 wt%) 
 
trehalose (77.5 wt %) 










4.3.4 Results and discussion. Nanocarriers prepared and stored as aqueous  
dispersion are known to undergo physical and chemical changes over time.  Therefore, 
conversion of nanocarriers dispersions to a powder form is highly desired to improve the 
long-term stability.  The drying method, process parameters and formulation excipients need 
to be carefully selected to ensure that nanocarriers can be re-dispersed without any significant 
size change, aggregation or loss of drug content. Furthermore, the spray dried powders 
should remain stable with low residual moisture content, to prevent chemical degradation of 
the formulation components.   In this study, selected PTX-micelles, PTX-liposomes and 
PTX-SLNs were successfully spray dried with either trehalose or a mixture of trehalose and 
L-leucine to stabilize the nanocarriers.  The choice of spray drying excipients did not 
significantly affect the yield, which ranged between 71.5% to 83.5% across all spray dried 
powder formulations (table 4.10 and figure 4.53).  Many spray dried powders contain 
carbohydrates in their amorphous state and since amorphous components are 
thermodynamically unstable and there is a driving force for crystallization to occur, a high 
transition temperature of powders is highly desirable.  Trehalose comprises the bulk of the 
spray dried formulations and was selected due to the high transition temperature. Increased 
moisture content can significantly decrease the transition temperature of spray dried powders, 
since water acts as a plasticizer, causing the mobilization of amorphous content [92].  
Consequently, powders with increased moisture content can have reduced transition 
temperatures, increasing the chances of forming physically unstable powders.  The oven KF 
results showed that the residual moisture content for all spray dried powders was very low at 
values <2% (table 4.11) and did not affect the transition temperatures of all spray dried 
formulations. This was demonstrated through the DSC results showing mid-point transition 
temperature values ranging between 95.07 ± 0.86 °C and 100.77 ± 0.00 °C (table 4.12) 
(figures 4.54 to 4.59) which are representative of trehalose.  SEM images showed smooth 
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surface and spherical morphology of powders spray dried with trehalose.  In contrast, 
powders spray dried with both trehalose and L-leucine showed corrugated particles with 
wrinkled morphology (figure 4.60).  Formulations with wrinkled morphology are attributed 
to the presence of L-leucine which precipitates out earlier in the drying process due to its 
lower solubility.  This results in a solid shell that collapses later in the drying process.  In 
contrast, formulations with highly water-soluble excipients such as trehalose continually 
shrink as liquid droplet dries, eventually forming particles with smooth morphology [88, 93, 
94].  To determine whether the nanocarriers had maintained their integrity after spray drying, 
the spray dried powders were reconstituted in purified water and the size/PDI was measured 
using DLS.  The results showed that the size of PTX-liposomes decreased from 107 nm to 
93.33 nm and the PDI decreased from 0.236 to 0.149 after spray drying with trehalose (table 
4.13 and 4.14, figure 4.61 and 4.62).  The same trend was observed for PTX-SLNs which 
showed a decrease in size from 90.80 nm to 74.20 nm (table 4.13 and table 4.14, figure 4.63). 
Particle size reduction in the presence of cryoprotectants has been recently observed and may 
be due to the interactions of trehalose with the nanocarrier [95].  Conversely, the sizes of 
liposomes increased from 107.60 nm to 138.53 nm when spray drying with trehalose and L-
leucine (figure 4.61, table 4.13).  This effect has previously been observed where 
concentrations of L-leucine at 1% (w/w) increased the size of liposomes significantly after 
spray drying [89].  This is likely due to the partitioning of hydrophobic amino acid L-leucine 
into the lipid membrane during drying, causing aggregation of the vesicles [89].  
Furthermore, it has also been demonstrated that amino acids with hydrocarbon side chains 
can cause damage to the lipid membranes of vesicles during freeze/thaw processes [96].  L-
leucine also influenced the size and PDI of PTX-SLNs since these powders did not dissolve 
completely upon reconstitution and required syringe filtration to remove undissolved 
particles.  Despite these changes, all spray dried PTX-liposomes and PTX-SLNs maintained 
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nanosizes close to 100 nm upon reconstitution. The stability of reconstituted PTX-SLNs and 
PTX-liposomes was determined by measuring the size, PDI and paclitaxel content over 7 
days at room temperature or at 4°C (figures 4.67 to 4.72).  The results showed no significant 
change in size, PDI and paclitaxel content over 7 days at 4°C.  There was also no significant 
change in the size and PDI of PTX-SLNs and PTX-liposomes at room temperature over 7 
days.  However, a decrease in the paclitaxel content of nanocarriers was observed over 7 days 
at room temperature except for PTX-SLNs and PTX-micelles spray dried in trehalose. 
Overall, the short-term stability studies showed that the reconstituted nanocarriers were stable 



























Table 4.10: Yields of spray dried formulations 
 






















Table 4.11: Residual moisture content of spray dried formulations (n=3) 
 
Formulation  Water (%) 
PTX-micelles/trehalose 1.29 ± 0.05 
PTX-liposomes/trehalose 1.85 ± 0.01 
PTX-SLN/trehalose 1.42 ± 0.01 
PTX-micelles/trehalose/leucine 1.08 ± 0.03 
PTX-liposomes/trehalose/leucine 1.44 ± 0.04 







Table 4.12: Transition temperatures of spray dried formulations (n=3) 
 
Formulation  Tg Onset (°C) Mid-Point Tg (°C) 
PTX-micelles/trehalose 97.65 ± 0.83 100.77 ± 0.00 
PTX-liposomes/trehalose 94.26 ± 2.97 98.91 ± 0.00 
PTX-SLN/trehalose 96.33 ± 0.02 98.10 ± 0.10 
Liposomes/Trehalose/Leucine 90.98 ± 0.80 95.17 ± 1.43 
Micelles/Trehalose/Leucine 92.11 ± 0.09 95.07 ± 0.86 















































Figure 4.60: Scanning Electron Microscope images of spray dried formulations (PTX-


















Table 4.13: Sizes of paclitaxel-loaded liposomes and solid lipid nanoparticles before and after 









Table 4.14: PDI of paclitaxel-loaded liposomes and solid lipid nanoparticles before and after 
spray drying (SD) (n=3) 
 
 
Formulation  PDI before SD PDI after SD  
in trehalose  
 
PDI after SD in 
trehalose/leucine  
PTX-liposomes  0.236 ± 0.001  0.149 ± 0.007 0.237 ± 0.003 
PTX-SLN  0.236 ± 0.002 0.224 ± 0.005 0.131 ± 0.025 
PTX-micelles ND ND ND 














Formulation Size before SD (nm) Size after SD  
in trehalose (nm) 
 
Size after SD in 
trehalose/leucine (nm) 
PTX-liposomes 107.60 ± 3.10 93.33 ± 2.95 138.53 ±17.31 
PTX-SLN 90.80 ± 1.11 74.20 ± 2.95 121.20 ± 8.98 





















































































Figure 4.65: Size of reconstituted spray dried paclitaxel-loaded liposomes and solid lipid 









Figure 4.66: PDI of reconstituted spray dried paclitaxel-loaded liposomes and solid lipid 





Figure 4.67: Size of reconstituted spray dried paclitaxel-loaded liposomes and solid lipid 









Figure 4.68: PDI of reconstituted spray dried paclitaxel-loaded liposomes and solid lipid 





Figure 4.69: Graph showing the paclitaxel content of spray dried micelles, liposomes and 









Figure 4.70: Graph showing the paclitaxel content of spray dried micelles, liposomes and 




Chapter 5: In Vivo Efficacy of Paclitaxel-loaded Micelles, Liposomes and SLNs 
 
5.1. Introduction 
To evaluate the in vivo efficacy of drug-loaded nanocarriers, xenograft models of 
human tumors grown in immunodeficient mice are developed by injection or implantation of 
human tumor cells in mice.  Once tumor growth has been established, mice are injected with 
drug-loaded nanocarriers and the anti-cancer efficacy can be determined by evaluating tumor 
growth progression over time and determination of the tumor mass at the end of the study.  
Other parameters such as body weight can be monitored throughout the course of the study to 
determine toxic effects of nanocarriers.  To maximize therapeutic efficacy, nanocarriers must 
demonstrate sufficient stability for extended in vivo circulation half-life, reduced drug leakage 
during circulation, maintenance of nanosize for tumor penetration and degradation for reduced 
systemic toxicity [97].  In this study, nanocarriers spray dried with trehalose were selected to 
compare the in vivo anti-cancer efficacy of PTX-micelles, PTX-SLNs and PTX-liposomes.   
5.2 Materials 
Spray dried PTX-micelles, PTX-liposomes and PTX-SLNs were prepared at 
AstraZeneca (SSF, CA). Cremophor EL was purchased from Spectrum Chemicals. The 
following materials were purchased by LoveLace Biomedical: A375 adherent malignant 
human melanoma cell line was obtained from ATTC (VA, USA). NCI Athymic NCr-nu/nu 
mice were purchased from Charles River Laboratories (San Diego CA, USA).  
5.3  Methods 
The in vivo animal study was conducted by Lovelace Biomedical (Albuquerque, NM) 
according to protocol (No. FY17-078) reviewed and approved by the Institutional Animal 
Care and Use Committee (IACUC).  The tumor regression effect was evaluated in 3 to 5-
week-old (15 to 25g) female NCI Athymic NCr-nu/nu mice obtained from Charles River 
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Laboratories.  All animals were injected with A375 human melanoma cells at a target of 106 
cells per animal by subcutaneous injection into the right or left posterior flank or on the back.  
Following tumor growth, animals were randomized into five treatment groups with targeted 
minimum group sizes of six mice per treatment group: (Trehalose, Taxol, PTX-micelles, 
PTX-liposomes and PTX-SLNs).  PTX-micelles, PTX-liposomes and PTX-SLNs were 
provided to LoveLace Biomedical in spray dried powder form and were reconstituted in 
sterile water for injection prior to in vivo administration.  Each group was treated by tail vein 
injection twice weekly and treatments were given at a paclitaxel dose of 50µg/kg for up to 4 
weeks.  The tumor volume was measured three times weekly using equation 5.1[98]: 
 
Equation 5.1  V = length * (width)2/2.   
 
The body weight of mice in each group was measured three times weekly.  Tumor volume 
and weight and body weight were determined at necropsy. Mice were euthanized based on 
the moribund/euthanasia criteria according to LoveLace biomedical protocol, which includes, 
difficulty or inability to reach food or water, reluctance to move when stimulated to do so, 
25% or greater pre-challenge body weight loss from the highest body weight measurement 
and tumor volume sizes reaching over 4000 mm3.  The data was analyzed by GraphPad Prism 
and the software was used to plot tumor volume v/s treatment day and the differences in 
tumor volume were statistically evaluated.  The differences in tumor volume between groups 
were compared using repeated-measures one-way ANOVA (mixed-effects model) followed 
by Tukey post hoc comparisons.  A p value <0.05 was considered statistically significant.  
The tumor growth inhibition (TGI) was calculated using equation 5.2, where T indicates the 
mean tumor volume of the treatment group and C indicates the mean tumor volume of the 
control group [99].  In vitro-in vivo correlations were analyzed by simple linear regression. 
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Equation 5.2   TGI (%) = (1-T/C) *100 
 
5.4 Results and Discussion 
The anti-tumor efficacy of PTX-micelles, PTX-liposomes and PTX-SLNs was 
evaluated in tumor-bearing mice.  For the control group (trehalose), PTX-micelle group and 
PTX-liposomes group, a number of mice were either moribund or had died on day 26 and 29 
(figure 5.1).  The statistical analysis results showed significant differences in tumor volumes 
between groups  (p<0.0001).  Tukey’s multiple comparison test revealed statistically 
significant differences in tumor volumes between control and taxol groups (p<0.01) and 
between control and PTX-SLN (p<0.01) groups, where tumor volumes in taxol and PTX-
SLN groups were smaller than those in the control group.  There was no statistically 
significant difference in tumor volumes between the control group vs PTX-micelles (p=0.97) 
or PTX-liposomes (p=0.99).  When comparing the treatment groups, PTX-SLNs 
demonstrated statistically significantly smaller tumor sizes compared to PTX-liposomes 
(p<0.02) and PTX-micelles (p<0.001).  After 24 days of treatment, the percent tumor growth 
inhibition was only 9.7% and 20.2% for PTX-micelles and PTX-liposomes compared to the 
control (table 5.1).  Compared to PTX-micelles and PTX-liposomes, PTX-SLNs inhibited the 
tumor growth as much as 50.3% (table 5.1).  At the end of the study, the reduction in tumor 
mass was the lowest for mice treated with PTX-SLNs and the largest for mice in the control, 
PTX-micelles and PTX-liposome groups (figure 5.2, table 5.2).  These tumor mass results 
correlated well the measured tumor volumes at the end of the study (R2=0.93) (figure 5.3).  
For all groups, there was no significant body weight loss observed (figure 5.4).  The results 
shown in figure 5.5 and 5.6 show that the tumor growth inhibition effect of PTX-micelles, 
PTX-liposomes and PTX-SLNs correlate well with the in vitro t50% (R2=0.94) and the in vitro 
rate constants in human serum (R2=0.65).  Overall, the results showed that PTX-SLNs 
demonstrated higher therapeutic efficacy compared to PTX-micelles and PTX-liposomes.  A 
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plausible conclusion from the in vitro-in vivo correlation results is that the t50% and rate 
constants determined in human serum is indicative of the ability of the nanocarrier to stay in 



















Figure 5.1: Graph showing the average tumor volume over 29 days for mice treated with 







Table 5.1: Percent tumor growth inhibition values with respect to control at 24 days  
 





























Figure 5.2: Graph showing the terminal tumor mass at the end of the study for the various 
treatments  
























Table 5.2: Average tumor mass at the end of the study for mice treated with trehalose, Taxol, 
PTX-micelles,  PTX-liposomes and PTX-solid lipid nanoparticles 
 
Formulation  Average tumor mass  
at the end of the study (grams) 
Trehalose 2.38 ± 1.95 
PTX-micelles 2.31 ± 1.81 
PTX-liposomes 2.23 ± 1.57 
Taxol 1.76 ± 1.21 
















Figure 5.3: Graph showing the correlation between tumor mass and tumor volume at the end 








Figure 5.4: Average body weights of mice treated with trehalose, Taxol, PTX-micelles, PTX-










Figure 5.5: Graph demonstrating in vitro-in vivo correlation between time to release 50% of 
drug (t50%) and percent tumor growth inhibition for PTX-micelles, PTX-liposomes and PTX-


















Figure 5.6: Graph demonstrating in vitro-in vivo correlation between rate constants and 











Chapter 6: Summary and Conclusions 
 
 
Cancer is one of the major causes of death worldwide and chemotherapy is the  
mainstay of treatment.  However, conventional chemotherapy has limitations such as the 
development of multidrug resistance, low selectivity for target tissue and toxic side effects 
that have negative consequences for the health and well-being of cancer patients.  Many 
chemotherapeutic agents such as paclitaxel have poor aqueous solubility, requiring the use of 
other excipients to aid solubilization for effective intravenous administration.   For example, 
paclitaxel (Taxol) is currently formulated with cremophor EL, which is a toxic excipient and 
has been known to cause severe side effects [38].  To overcome these challenges, 
nanocarriers can be used to encapsulate and deliver hydrophobic anti-cancer agents to tumor 
tissue by passive and active targeting mechanisms.  Despite these advantages, premature drug 
leakage is one of the major reasons for inefficient drug delivery to the tumor. Drug diffusion 
out of the nanocarriers or destabilization of drug loaded nanocarriers by physiological 
interactions with blood cells, serum proteins, and cell membranes upon systemic 
administration contribute to premature drug release.  Therefore, developing stable anti-cancer 
nanocarriers is key for the successful clinical translation of these nanomedicines.   
In this study, targeted micelles, liposomes and SLNs of similar composition were  
prepared and their potential was evaluated by comparing physicochemical characteristics, in 
vitro stability, in vitro release rates and in vivo efficacy.  Micelles were formed through the 
self-assembly of PAs comprising of an LDV peptide region conjugated to single chain 
palmitic acid via PEG2 hydrophilic linkers.  PAs self-assembled in aqueous solution at CMC 
values ranging between 23.68 ± 0.72µM to 38.76 ± 2.27µM.  Liposomes and SLNs of similar 
composition to micelles were prepared using palmitic acid derived lipids and PAs to impart 
targeting properties.  In the vitro stability studies using FRET showed that targeted micelles, 
liposomes and SLNs were stable when diluted in aqueous medium over 24 hours, however 
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the stability decreased in the presence of human serum, where micelles were the least stable 
and SLNs the most stable. The same trend was observed for the in vitro paclitaxel release 
profiles, where targeted PTX-micelles had the fastest release rate and PTX-SLNs exhibited 
the slowest release rate.  PTX-micelles, PTX-liposomes and PTX-SLNs were spray dried to 
arrest drug passive diffusion and enhance long term stability.  The results showed that 
compared to initial aqueous dispersions, spray dried formulations maintained their nanosize 
and paclitaxel content over 7 days at 4⁰C.  At room temperature, the paclitaxel content of  
PTX-micelle/trehalose and PTX-SLN/trehalose formulations were maintained over 7 days 
and all formulations maintained their nanosize.  PTX-micelles, PTX-liposomes and PTX-
SLNs were further evaluated to determine the anti-cancer in vivo efficacy in an A375 
melanoma xenograft mouse model.  The results showed a significant delay in tumor growth 
for mice treated with PTX-SLNs compared with control, PTX-micelle and PTX-liposome 
groups.  Overall, the in vitro results showed that targeted PTX-SLNs were the least prone to 
disruption in human serum and were able to encapsulate paclitaxel over longer periods of 
time under sink conditions compared to PTX-micelles and PTX-liposomes.  Furthermore, 
PTX-SLNs demonstrated superior anti-cancer efficacy in vivo compared to PTX-micelles 
and PTX-liposomes and could be promising vehicles for drug targeting and delivery. Future 
work could involve exploring other nanocarriers for stability characterization.  The use of 
other materials for nanocarrier preparation such as polymers could be investigated.  
Additionally, escalation of dose can be implemented to achieve better therapeutic efficacy 
with tumor regression.  
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